Novo Integrated Sciences (NVOS) 10-K 14 Dec 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Aug. 31, 2023	Dec. 14, 2023	Feb. 28, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Aug. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--08-31
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Title of 12(b) Security	Common Stock
Trading Symbol	NVOS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 16,082,780
Entity Common Stock, Shares Outstanding		17,291,192
Documents Incorporated by Reference [Text Block]	None
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	5525
Auditor Name	Fruci & Associates II, PLLC
Auditor Location	Spokane, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Current Assets:
Cash and cash equivalents	$ 416,323	$ 2,178,687
Accounts receivable, net	1,467,028	1,017,405
Inventory, net	1,106,983	879,033
Other receivables	1,051,584	1,085,335
Prepaid expenses and other current assets	346,171	571,335
Total current assets	4,388,089	5,731,795
Property and equipment, net	5,390,038	5,800,648
Intangible assets, net	16,218,539	18,840,619
Right-of-use assets, net	1,983,898	2,673,934
Goodwill	7,582,483	7,825,844
TOTAL ASSETS	35,563,047	40,872,840
Current Liabilities:
Accounts payable	3,513,842	1,800,268
Accrued expenses	1,233,549	1,116,125
Accrued interest (including amounts to related parties)	382,666	454,189
Government loans and notes payable, current portion	277,405
Convertible notes payable, net of discount of $459,332	558,668	9,099,654
Contingent liability	61,767	534,595
Debentures, related parties, current portion	916,824
Finance lease liability, current portion	11,744	8,890
Operating lease liability, current portion	415,392	582,088
Total current liabilities	7,904,858	14,074,706
Debentures, related parties, net of current portion		946,250
Government loans and notes payable, net of current portion	65,038	161,460
Finance lease liability, net of current portion		12,076
Operating lease liability, net of current portion	1,693,577	2,185,329
Deferred tax liability	1,400,499	1,445,448
TOTAL LIABILITIES	11,063,972	18,825,269
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 15,759,325 and 3,118,063 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively	15,760	3,118
Additional paid-in capital	90,973,316	66,084,887
Common stock to be issued (91,138 and 414,965 shares at August 31, 2023 and August 31, 2022)	1,217,293	9,474,807
Other comprehensive (loss) income	(357,383)	560,836
Accumulated deficit	(67,033,041)	(53,818,489)
Total Novo Integrated Sciences, Inc. stockholders’ equity	24,815,945	22,305,159
Noncontrolling interest	(316,870)	(257,588)
Total stockholders’ equity	24,499,075	22,047,571
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	35,563,047	40,872,840
Related Party [Member]
Current Liabilities:
Due to related parties	$ 533,001	$ 478,897

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Statement of Financial Position [Abstract]
Convertible notes payable net of discount current	$ 459,332	$ 459,332
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	15,759,325	3,118,063
Common stock, shares outstanding	15,759,325	3,118,063
Common stock to be issued, shares	91,138	414,965

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Income Statement [Abstract]
Revenues	$ 12,572,019	$ 11,737,937
Cost of revenues	7,619,304	6,938,699
Gross profit	4,952,715	4,799,238
Operating expenses:
Selling expenses	15,149	20,702
General and administrative expenses	13,490,728	14,364,639
Impairment of assets		14,083,531
Goodwill impairment		1,357,043
Total operating expenses	13,505,877	29,825,915
Loss from operations	(8,553,162)	(25,026,677)
Non-operating income (expense)
Interest income	9,027	169,088
Interest expense	(360,571)	(1,594,275)
Other income	607,589
Amortization of debt discount	(4,757,121)	(5,973,973)
Foreign currency transaction losses	(215,206)	(641,643)
Total other income (expense)	(4,716,282)	(8,040,803)
Loss before income taxes	(13,269,444)	(33,067,480)
Income tax expense (recovery)		(22,302)
Net loss	(13,269,444)	(33,045,178)
Net loss attributed to noncontrolling interest	(54,892)	(195,963)
Net loss attributed to Novo Integrated Sciences, Inc.	(13,214,552)	(32,849,215)
Comprehensive loss:
Foreign currency translation loss	(922,609)	(431,605)
Comprehensive loss:	$ (14,192,053)	$ (33,476,783)
Weighted average common shares outstanding - basic	10,165,548	2,913,263
Weighted average common shares outstanding - diluted	10,165,548	2,913,263
Net loss per common share - basic	$ (1.30)	$ (11.28)
Net loss per common share - diluted	$ (1.30)	$ (11.28)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock To Be Issued [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total Novo Stockholders Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Aug. 31, 2021	$ 2,661	$ 54,603,345	$ 9,236,607	$ 991,077	$ (20,969,274)	$ 43,864,416	$ (60,261)	$ 43,804,155
Balance, shares at Aug. 31, 2021	2,661,014
Common stock for services	$ 75	1,329,675				1,329,750		1,329,750
Common stock for services, shares	75,000
Common stock issued as collateral and held in escrow	$ 200	(200)
Common stock issued as collateral and held in escrow, shares	200,000
Share issuance for convertible debt settlement	$ 64	1,272,930				1,272,994		1,272,994
Share issuance for convertible debt settlement, shares	63,653
Common stock issued for acquisitions	$ 80	1,703,920				1,704,000		1,704,000
Common stock issued for acquisitions, shares	80,000
Common stock to be issued for acquisitions			1,433,475			1,433,475		1,433,475
Value of warrants issued with convertible notes		$ 5,553,290				$ 5,553,290		$ 5,553,290
Issuance of common stock to be issued	38	1,195,237	(1,195,275)
Issuance of common stock to be issued, shares	38,396
Fair value of stock options		$ 426,690				$ 426,690		$ 426,690
Foreign currency translation loss				(430,241)		(430,241)	(1,364)	(431,605)
Net loss					(32,849,215)	(32,849,215)	(195,963)	(33,045,178)
Ending balance, value at Aug. 31, 2022	$ 3,118	66,084,887	9,474,807	560,836	(53,818,489)	22,305,159	(257,588)	22,047,571
Balance, shares at Aug. 31, 2022	3,118,063
Common stock for services	$ 359	480,233				480,592		480,592
Common stock for services, shares	358,500
Share issuance for convertible debt settlement	$ 10,178	9,957,962				9,968,140		9,968,140
Share issuance for convertible debt settlement, shares	10,177,834
Value of warrants issued with convertible notes		$ 257,994				$ 257,994		$ 257,994
Issuance of common stock to be issued	324	8,257,190	(8,257,514)
Issuance of common stock to be issued, shares	323,827
Fair value of stock options		$ 385,335				$ 385,335		$ 385,335
Foreign currency translation loss				(918,219)		(918,219)	(4,390)	(922,609)
Net loss					(13,214,552)	(13,214,552)	(54,892)	(13,269,444)
Units issued for cash, net of offering costs	$ 400	1,794,600				1,795,000		$ 1,795,000
Units issued for cash, net of offering costs, shares	400,000							400,000
Cashless exercise of warrants	$ 583	1,421,000				1,421,583		$ 1,421,583
Cashless exercise of warrants, shares	583,334
Exercise of warrants for cash	$ 533	532,067				532,600		532,600
Exercise of warrants for cash, shares	532,600
Shares issued with convertible notes	$ 265	247,622				247,887		247,887
Shares issued with convertible notes, shares	265,167
Beneficial conversion feature upon issuance on convertible debt		164,046				164,046		164,046
Extinguishment of derivative liability due to conversion		1,390,380				1,390,380		1,390,380
Ending balance, value at Aug. 31, 2023	$ 15,760	$ 90,973,316	$ 1,217,293	$ (357,383)	$ (67,033,041)	$ 24,815,945	$ (316,870)	$ 24,499,075
Balance, shares at Aug. 31, 2023	15,759,325

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,269,444)	$ (33,045,178)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,302,754	3,019,253
Fair value of vested stock options	385,335	426,690
Financing costs for debt extension	1,421,583
Default payment and interest paid through common share issuance	205,349
Common stock issued for services	480,592	1,329,750
Operating lease expense	797,515	852,580
Amortization of debt discount	4,757,121	5,973,973
Foreign currency transaction losses	215,206	641,643
Impairment of assets		14,083,531
Other receivables write-off		299,672
Goodwill impairment		1,357,043
Changes in operating assets and liabilities:
Accounts receivable	(597,191)	457,006
Inventory	(255,781)	(527,397)
Prepaid expenses and other current assets	210,382	(369,647)
Accounts payable	1,770,589	283,234
Accrued expenses	153,598	38,743
Accrued interest	(58,066)	101,353
Operating lease liability	(762,852)	(806,394)
Net cash used in operating activities	(2,243,315)	(5,884,145)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(49,224)	(190,168)
Cash acquired with acquisition		57,489
Collection of other receivable		296,138
Net cash (used in) provided by investing activities	(49,224)	163,459
CASH FLOWS FROM FINANCING ACTIVITIES:
Receipts from related parties	7,206	16,600
Proceeds from notes payable	222,780
Repayments of notes payable	(37,130)	(10,591,115)
Repayments of finance leases	(8,611)	(18,435)
Proceeds from issuance of convertible notes	1,285,903	15,270,000
Repayment of convertible notes	(3,033,888)	(5,104,167)
Proceeds from the sale of common stock, net of offering costs	1,795,000
Proceeds from exercise of warrants	532,600
Net cash provided by (used in) financing activities	763,860	(427,117)
Effect of exchange rate changes on cash and cash equivalents	(233,685)	33,328
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,762,364)	(6,114,475)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	2,178,687	8,293,162
CASH AND CASH EQUIVALENTS, END OF YEAR	416,323	2,178,687
CASH PAID FOR:
Interest	432,094	1,502,819
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for convertible debt	9,968,140	1,272,994
Common stock issued for acquisition		1,704,000
Warrants issued with convertible notes	257,994	5,553,290
Beneficial conversion feature upon issuance of convertible notes	164,046
Debt discount recognized on derivative liability	1,390,380
Extinguishment of derivative liability due to conversion	1,390,380
Debt discount recognized on convertible note	975,024
Common stock issued with convertible notes	$ 247,887

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (13,214,552)	$ (32,849,215)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Aug. 31, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Aug. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 1,677,974 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split Basis of Presentation The accompanying consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the Parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying consolidated financial statements were translated and presented in USD. Going Concern The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the consolidated financial statements are issued. The Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit as at of August 31, 2023. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the consolidated financial statements are issued. To alleviate these conditions, the Company is currently in the process of raising funds through debt financing and a subsequent public offering in the United States. As the Company’s funding activities are ongoing, there can be no assurances that the Company will be able to secure funding on terms that are acceptable to the Company. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used August 31, 2023 August 31, 2022 Period end: CAD to USD exchange rate $ 0.7390 $ 0.7627 Average period: CAD to USD exchange rate $ 0.7426 $ 0.7864

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Aug. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2023 and 2022, the allowance for uncollectible accounts receivable was $ 864,215 992,329 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of August 31, 2023 and 2022, the Company’s allowance for slow moving or obsolete inventory was $ nil 1,027,670 Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the years ended August 31, 2023 and 2022, the Company wrote off $ nil 299,672 225,924 73,748 Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2023 and 2022, the Company believes there was $ nil 14,083,531 Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $ 1,357,043 no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Ending balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of August 31, 2023 and 2022, respectively, the Company did not identify any financial assets and liabilities required to be presented on the consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs. Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ASU No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying consolidated balance sheets. Sales returns and allowances were insignificant for the years ended August 31, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 1,777,678 1,060,950 581,715 91,138 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation losses of $ 922,609 431,605 Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting two Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In March 2020, the FASB issued ASU No. 2020-04 providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020, could be applied through December 31, 2022. In December 2022, the FASB issued No 2022-06 extending the sunset date of the relief provided under ASU No. 2020-04 to December 31, 2024. The ASU has not impacted these consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2024. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The guidance allows for either full retrospective adoption or modified retrospective adoption. The ASU is effective for the fiscal years beginning after December 15, 2023 and early adoption is permitted. The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Aug. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At August 31, 2023 and 2022, the amount due to related parties was $ 533,001 478,897 451,137 21,267 6 60,597 13.75 394,405 21,949 6 62,543 13.75 The remaining principal balance of debentures due to related parties at August 31, 2023 and 2022 was $ 916,824 946,250

Inventory

Inventory	12 Months Ended
	Aug. 31, 2023
Inventory Disclosure [Abstract]
Inventory	Note 4 – Inventory Inventory at August 31, 2023 and 2022 consisted of the following: Schedule of Inventory 2023 2022 Raw materials $ 388,391 $ 1,259,954 Work in process 81,696 139,333 Finished Goods 636,896 507,416 Inventory Gross 1,106,983 1,906,703 Allowance for slow moving and obsolete inventory - (1,027,670 ) Inventory, net $ 1,106,983 $ 879,033

Accounts Receivables, net

Accounts Receivables, net	12 Months Ended
	Aug. 31, 2023
Receivables [Abstract]
Accounts Receivables, net	Note 5 – Accounts Receivables, net Accounts receivables, net at August 31, 2023 and 2022 consisted of the following: Schedule of Accounts Receivable, Net 2023 2022 Trade receivables $ 2,223,243 $ 1,829,475 Amounts earned but not billed 108,000 180,259 Accounts receivables gross 2,331,243 2,009,734 Allowance for doubtful accounts (864,215 ) (992,329 ) Accounts receivable, net $ 1,467,028 $ 1,017,405

Other Receivables

Other Receivables	12 Months Ended
	Aug. 31, 2023
Receivables [Abstract]
Other Receivables	Note 6 – Other Receivables Other receivables at August 31, 2023 and 2022 consisted of the following: Schedule of Other Receivables 2023 2022 Advance to corporation; accrues interest at 12 January 31, 2024 73,900 76,272 Advance to corporation; accrues interest at 12 February 1, 2024 534,386 551,536 Advance to corporation; accrues interest at 10 February 1, 2024 443,298 457,527 Total other receivables 1,051,584 1,085,335 Current portion (1,051,584 ) (1,085,335 ) Long-term portion $ - $ -

Property and Equipment

Property and Equipment	12 Months Ended
	Aug. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment at August 31, 2023 and 2022 consisted of the following: Schedule of Property and Equipment 2023 2022 Land $ 443,400 $ 457,631 Building 3,325,500 3,432,232 Leasehold improvements 841,371 868,375 Clinical equipment 1,916,681 1,927,639 Computer equipment 33,504 34,579 Office equipment 44,502 45,406 Furniture and fixtures 38,289 39,518 Property and Equipment gross 6,643,247 6,805,380 Accumulated depreciation (1,253,209 ) (1,004,732 ) Total $ 5,390,038 $ 5,800,648 Depreciation expense for the years ended August 31, 2023 and 2022 was $ 292,041 323,040 Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible Assets

Intangible Assets	12 Months Ended
	Aug. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets at August 31, 2023 and 2022 consisted of the following: Schedule of Intangible Assets 2023 2022 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,497,746 8,059,386 Customer relationships 2,291,058 2,320,154 Brand names 1,928,421 1,990,314 Finite lived intangible assets, gross 23,290,546 23,943,175 Accumulated amortization (7,072,007 ) (5,102,556 ) Total $ 16,218,539 $ 18,840,619 Amortization expense for the years ended August 31, 2023 and 2022 was $ 2,010,713 2,696,213 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Years Ending August 31, 2024 $ 2,006,623 2025 1,944,426 2026 1,494,169 2027 1,288,217 2028 848,582 Thereafter 8,636,522 Total $ 16,218,539 On January 7, 2019, 2478659 Ontario Ltd. (“247”) and Kainai Cooperative (“Kainai”) entered into a Joint Venture Agreement (the “Joint Venture Agreement”) for the purpose of developing, managing and arranging for financing of greenhouse and farming projects involving hemp and cannabis cash crops on Kainai related lands, and developing additional infrastructure projects creating jobs and food supply to local communities. On January 8, 2019, we and 247 entered into an Agreement of Transfer and Assignment, pursuant to which 247 agreed to sell, assign and transfer to the Company all rights, contracts, contacts and any and all other assets related in any way to the Joint Venture Agreement. Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai. 50 120,000 21,600,000 nil 10,026,679 On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell (the “Acquisition”), proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada (the “Intellectual Property”). Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 80,000 5,248,000 nil 1,858,179 On February 26, 2019, the Company and NHL entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”), pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”). Pursuant to the terms of the Cloud DX License, Cloud DX also agreed to sell, and NHL agreed to purchase, 4,000 The Cloud DX License granted to NHL and its majority-owned subsidiaries, holding companies, divisions and affiliates, other than physiotherapy clinics owned and operated by Closing The Gap Healthcare Inc., the right to use and sub-license the Licensed Software and re-sell the Bundled Devices pursuant to the terms of the Cloud DX License in the physical therapy clinic marketplace in North America in exchange for the purchase price as set forth below: ● Upon the closing, the Company issued 45,835 1,000,000 758,567 ● Cloud DX agreed to invoice CAD$ 250,000 189,642 On March 9, 2020, the Company and NHL entered into that certain First Amendment to Cloud DX Perpetual Software License Agreement (the “Cloud DX Amendment”) with Cloud DX, effective March 6, 2020, pursuant to which the parties thereto agreed that the CAD$ 250,000 186,231 4,656 200,000 5,000 As at August 31, 2022, the remaining value of the software license was determined to be fully impaired. As of August 31, 2023, NHL and Cloud DX no longer have a contractual relationship. In connection with the acquisition of PRO-DIP (see Note 16), the Company acquired intellectual property valued at $ 455,752 nil 52,752 In connection with the acquisition of Acenzia (See Note 16), the Company acquired the following intangible assets: intellectual property valued at $ 2,875,000 806,000 2,115,000 In connection with the acquisition of Terragenx (see Note 16), the Company acquired intellectual property valued at $ 1,179,361 In connection with the acquisition of 1285 Canada (see Note 16), the Company acquired customer relationships valued at $ 31,101 In connection with the acquisition of Poling Taddeo Hovius Physiotherapy Professional Corp. (see Note 16), the Company acquired customer relationships valued at $ 151,686 In connection with the acquisition of Clinical Consultants International LLC (see Note 16), the Company acquired customer relationships valued at $ 1,701,814 nil 317,314

Accrued Expenses

Accrued Expenses	12 Months Ended
	Aug. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 – Accrued Expenses Accrued expenses at August 31, 2023 and 2022 consisted of the following: Schedule of Accrued Expenses 2023 2022 Accrued liabilities $ 961,897 $ 884,024 Accrued payroll 236,218 195,214 Unearned revenue 35,434 36,887 Accrued expense $ 1,233,549 $ 1,116,125

Government Loans and Note Payab

Government Loans and Note Payable and Government Subsidy	12 Months Ended
	Aug. 31, 2023
Government Loans And Note Payable And Government Subsidy
Government Loans and Note Payable and Government Subsidy	Note 10 – Government Loans and Note Payable and Government Subsidy Governmental loans and note payable at August 31, 2023 and 2022 consisted of the following: Schedule of Governmental Loans and Note Payable 2023 2022 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A) 88,680 91,526 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,693 29,614 Note payable received May 25, 2023 accruing interest at 18 73,900 - Note payable received May 10, 2023 accruing interest at 15 110,850 - Total government loans and notes payable 342,443 161,460 Less current portion (277,405 ) - Long-term portion $ 65,038 $ 161,460 (A) The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,560 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Years Ending August 31, 2024 $ 277,405 2025 6,408 2026 6,557 2027 6,714 2028 6,878 Thereafter 38,481 Total $ 342,443

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Aug. 31, 2023
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 20 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 583,334 20 December 14, 2025 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 11,409,200 5,257,466 5,257,466 1,666,666 1,140,000 8,064,132 On November 14, 2022, the $16.66m+ convertible notes were amended to provide the holders with conversion rights consisting of a conversion price to the first $ 1,000,000 (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. derivative liability 1,390,380 ● Expected life of 0.58 ● Volatility of 148.20 ● Dividend yield of 0 ● Risk free interest rate of 4.55 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible notes. During the year ended August 31, 2023, an aggregate of $ 8,396,666 32,559 8,527,835 1,000,000 1,390,380 nil nil During the year ended August 31, 2023, the Company amortized $ 4,241,429 nil During the year ended August 31, 2023, the Company made cash payments in the aggregate amount of $ 3,001,442 2,833,888 167,554 nil Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 33.50 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 22,388 33.50 The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $ 351,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 760,824 0 On June 1, 2022, the Company paid the balance owed on one of two Terragenx $ 1.875 948,874 1.875 192,188 November 29, 2022 937,500 On June 1, 2022, the Company and one of the two Terragenx $ 1.875 November 29, 2022 186,719 Effective February 16, 2023, aside from the Liquidated Damages Charge, the Jefferson Note was paid in full. On August 21, 2023, Jefferson converted the additional Liquidated Damages Charge and the interest thereon. On August 21, 2023, as a result of the conversion, the Company issued 236,511 Novo Integrated – Mast Hill Fund, L.P. $573,000 Note, SPA, and Warrant On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 February 23, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125 16 The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $ 2.50 86,327 ● Expected life of 5.0 ● Volatility of 252 ● Dividend yield of 0 ● Risk free interest rate of 4.09 As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 95,500 19.99 2,772,045 The principal amount of the $ 573,000 403,710 82,963 86,327 57,300 70,465 297,055 297,055 nil During the year ended August 31, 2023, the principal amount of $ 573,000 6,028 1,750 522,777 nil Novo Integrated – FirstFire Global Opportunities Fund, LLC $573,000 Note, SPA, and Warrant On March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire Global Opportunities Fund, LLC (“FirstFire”) pursuant to which the Company issued an 12 March 21, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125 16 The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $ 2.50 93,811 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.73 As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 95,500 1,000,000 The principal amount of the $ 573,000 389,057 90,132 93,811 57,300 35,628 The effective conversion price was determined to be $ 1.188 1.390 66,068 The combined total discount is $ 342,938 152,729 190,209 Novo Integrated – Mast Hill Fund, L.P.$445,000 Note, SPA, and Warrant On June 20, 2023, the Company entered into a securities purchase agreement (the “MH $445,000 SPA”) with Mast Hill, pursuant to which the Company issued an 12 June 20, 2024 445,000 77,662 12 44,500 400,500 1.75 Pursuant to the terms of the MH $445,000 Note, the Company agreed to pay accrued interest monthly as well as the MH $ 445,000 44,500 44,500 44,500 77,661 77,661 77,661 445,000 85 The Company may prepay the MH $445,000 Note at any time prior to the date that an Event of Default (as defined in the Note) (each an “MH $445,000 Event of Default”) occurs at an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any MH $445,000 Event of Default, the MH $445,000 Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued interest multiplied by 125 16 The MH $445,000 Warrant is exercisable for five years from June 20, 2023, at an exercise price of $ 2.50 445,000 77,856 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.96 As additional consideration for the purchase of the MH $445,000 Note and pursuant to the terms of the MH $445,000 SPA, the Company issued 74,167 1,772,045 The principal amount of the $ 445,000 292,351 74,793 77,856 44,500 39,904 The effective conversion price was determined to be $ 1.150 1.535 97,978 The combined total discount is $ 335,031 65,908 269,123 Specific to the MH $445,000 Note, on July 20, 2023, the Company made a monthly interest payment of $ 4,243 4,535

Debentures, related parties

Debentures, related parties	12 Months Ended
	Aug. 31, 2023
Debt Disclosure [Abstract]
Debentures, related parties	Note 12 – Debentures, related parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8 September 30, 2016 September 30, 2019 December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 4.11 the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At August 31, 2023 and 2022, the amount of debentures outstanding was $ 916,824 946,250

Leases

Leases	12 Months Ended
	Aug. 31, 2023
Leases
Leases	Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2031. The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2023 and 2022: Schedule of Lease Related Assets and Liabilities 2023 2022 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,983,898 $ 2,673,934 Total lease assets $ 1,983,898 $ 2,673,934 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 415,392 $ 582,088 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,693,577 2,185,329 Total lease liability $ 2,108,969 $ 2,767,417 Lease obligations at August 31, 2023 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2024 $ 579,780 2025 510,085 2026 509,330 2027 472,291 2028 254,187 Thereafter 300,769 Total payments 2,626,442 Amount representing interest (517,473 ) Lease obligation, net 2,108,969 Less lease obligation, current portion (415,392 ) Lease obligation, long-term portion $ 1,693,577 During the year ended August 31, 2023, the Company entered into new lease obligations of $nil. The lease expense for the years ended August 31, 2023 and 2022 was $ 797,515 852,580 772,655 806,394 At August 31, 2023, the weighted average remaining lease terms were 2.73 8% Finance leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5% The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2023 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (209,457 ) Net book value $ - Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2024 $ 11,810 Total payments 11,810 Amount representing interest (66 ) Lease obligation, net 11,744 Less lease obligation, current portion (11,744 ) Lease obligation, long-term portion $ -

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Aug. 31, 2023
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity Convertible preferred stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split As of August 31, 2023 and 2022 there were 15,759,325 3,118,063 During the fiscal year ended August 31, 2023, the Company issued: ● 400,000 5 The Company sold an aggregate of 400,000 2,000,000 400,000 400,000 three 400,000 5 400,000 five 400,000 5 140,000 7.0% 1,795,000 The total fair value of the 800,000 1,137,959 149.06% 206.90% 0% 2.55% 2.89% 2.956 3 5 ● 3,623 October 26, 2022 ● 291,667 November 15, 2022 ● 175,732 November 15, 2022 ● 3,916,596 3,825,307 February 28, 2023 ● 4,503,644 4,503,640 February 28, 2023 ● 890,711 757,103 February 28, 2023 ● 65,000 3 65,000 ● 115,935 ● 33,000 5 33,000 ● 33,000 3 33,000 ● 320,204 January 25, 2023 ● 95,500 February 24, 2023 ● 107,595 100,278 53,783 53,812 ● 160,000 3 160,000 ● 100,000 5 100,000 ● 95,500 March 22, 2023 ● 30,000 5 30,000 ● 30,000 3 30,000 ● 75,000 ● 74,167 ● 100,000 ● 33,500 ● 75,000 ● 75,000 ● 20,800 3 20,800 ● 20,800 5 20,800 ● 10,000 3 10,000 ● 30,000 5 30,000 ● 236,511 201,034 186,719 14,315 ● 522,777 580,778 During the fiscal year ended August 31, 2022, the Company issued: ● 3,500 64,750 ● 200,000 1,875,000 November 23, 2021 0 ● 5,000 65,500 ● 2,500 30,000 ● 6,500 78,000 ● 5,000 60,000 ● 5,000 64,500 ● 5,000 138,000 ● 2,500 69,000 ● 80,000 1,704,000 ● 5,000 107,000 ● 22,500 ● 62,395 1,244,444 3,405 ● 30,000 ● 5,000 ● 1,258 25,000 143 ● 15,896 Common Stock to be Issued As of August 31, 2023, in connection with the acquisition of Terragenx, 12858461 Canada Corp, and Poling Taddeo Hovius Physiotherapy Professional Corp (See Note 16), the Company has allotted and is obligated to issue 91,138 1,217,293 Stock Options and Warrants On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 50,000 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 100,000 86,490 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 450,000 the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022 and January 1, 2023. As of August 31, 2023, the 2021 Plan had 75,463 The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 184,960 22.90 3.14 $ 218,240 Granted 36,946 14.60 3.80 Expired - Forfeited (5,483 ) Exercised - Outstanding, August 31, 2022 216,423 21.50 2.53 $ 140,577 Granted 200,000 1.32 5.75 Expired (45,000 ) Exercised - Outstanding, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000 Exercisable, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000 The exercise price for stock options outstanding and exercisable at August 31, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423 For options granted during the year ended August 31, 2023 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 1.32 1.32 For options granted during the year ended August 31, 2022 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 13.72 14.24 18.01 19.00 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 385,335 426,690 The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the year ended August 31, 2023 and 2022: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2023 2022 Risk-free interest rate 3.74 % 0.93 3.01 % Expected life of the options 6 2.5 Expected volatility 254 % 267 281 % Expected dividend yield 0 % 0 % Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 238,805 33.50 5.12 $ - Granted 605,721 20.50 3.25 Forfeited - Exercised - Outstanding, August 31, 2022 844,526 24.18 3.50 $ - Granted 1,077,661 1.39 3.51 Forfeited - Exercised (1,115,933 ) Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Exercisable, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 The exercise price for warrants outstanding at August 31, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 267,400 1.00 277,661 2.50 806,254

Income Taxes

Income Taxes	12 Months Ended
	Aug. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes The Company’s Canadian subsidiaries are subject to the income tax laws of the Province of Ontario and the country of Canada. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of August 31, 2023 and 2022 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. The current and deferred income tax expenses for the years ended August 31, 2023 and 2022 were $nil. A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2023 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (3,515,747 ) $ (9,698,805 ) $ (13,214,552 ) Expected income tax benefit (931,672 ) -26.5 % (2,618,677 ) -27.0 % (3,550,349 ) Stock based compensation - 0.0 % 233,800 9.0 % 233,800 Change in valuation allowance 931,672 26.5 % 2,384,877 18.0 % 3,316,549 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2022 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (8,105,151 ) $ (24,744,064 ) $ (32,849,215 ) Expected income tax benefit (2,147,864 ) -26.5 % (6,680,897 ) -27.0 % (8,828,761 ) Stock based compensation - 0.0 % 474,239 17.4 % 474,239 Change in valuation allowance 2,147,864 26.5 % 6,206,658 9.6 % 8,354,522 $ - 0.0 % $ - 0.0 % $ - 0.0 % At August 31, 2023 and 2022, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2023 2022 Deferred tax asset: Net operating loss carryforwards $ 15,839,947 $ 12,523,398 Total deferred tax asset 15,839,947 12,523,398 Less: valuation allowance (15,839,947 ) (12,523,398 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,400,499 ) (1,445,448 ) Total deferred tax liability (1,400,499 ) (1,445,448 ) Net deferred tax liability $ (1,400,499 ) $ (1,445,448 ) The valuation allowance for the years ended August 31, 2023 and 2022 increased as a result of the Company generating additional net operating losses. The Company has recorded as of August 31, 2023 and 2022 a valuation allowance of $ 15,839,947 12,523,398 The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of August 31, 2023 and 2022. As of August 31, 2023, the Company has net operating loss carry-forward of approximately $ 10,124,095 10,055,712

Acquisitions

Acquisitions	12 Months Ended
	Aug. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Note 16 – Acquisitions Acquisition of Businesses Joint Venture Joint Venture Agreement with Farm 7 Group Inc. for the Kenya Agricultural Cooperative Project On August 14, 2023, the Company and Farm 7 Group Inc., a Canada corporation, completed a Joint Venture Agreement (the “Farm 7 JV”) to establish a joint venture entity in a Canadian jurisdiction, mutually acceptable to both parties, to assist in development, administration and the arrangement of structured financing for the implementation and commencement of the “Kenya Agricultural Cooperative Project”, in particular a Kenya centric agricultural project with executed uptake contracts for agricultural goods with a term of thirty years involving up to 9 million hectares of land participating under a cooperative structure. The Farm 7 JV provides for the annual distribution of the net profits 75% to F7 and 25% to the Company. As of August 31, 2023, were no further activity relating to Farm 7 JV. MiTelemed+ 50/50 Joint Venture with EK-Tech Solutions, Inc. On October 8, 2021, the Company and NHL completed a Joint Venture Agreement (the “MiTelemed+ JV”) with EK-Tech Solutions Inc. (“EK-Tech”) to establish the joint venture company MiTelemed+ Inc., an Ontario province Canada corporation (“MiTelemed+”), to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform. At closing, EK-Tech contributed all intellectual property, source code, and core data of the iTelemed platform, valued at CAD$ 1,500,000 185,000 Mullins Asset Purchase Agreement On November 17, 2021, the Company entered into that certain Asset Purchase Agreement (the “Mullins APA”), dated as of November 17, 2021, by and between the Company and Terence Mullins. Pursuant to the terms of the Mullins APA, Mr. Mullins agreed to sell, and the Company agreed to purchase, all of Mr. Mullins’ right, title and interest in and to certain assets (the “Mullins IP Assets”), in exchange for a purchase price of CAD$ 2,500,000 1,990,250 (a) CAD$ 2,000,000 1,592,200 (b) CAD$ 500,000 398,050 11,883 All shares issued or allotted under the terms and conditions of the Mullins APA are calculated at a value of $ 33.50 15.90 755,701 188,925 The amounts assigned to assets acquired are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. In addition, the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property. Terragenx Share Exchange Agreement On November 17, 2021, the Company and NHL, a wholly owned subsidiary of the Company, entered into that certain Share Exchange Agreement (the “Terra SEA”), dated as of November 17, 2021, by and among the Company, NHL, Terragenx Inc. (“Terra”), TMS Inc. (“TMS”), Shawn Mullins, Claude Fournier, and The Coles Optimum Health and Vitality Trust (“COHV” and collectively with TMS, Mr. Mullins and Mr. Fournier, the “Terra Shareholders”). Collectively, the Terra Shareholders owned 91 Pursuant to the terms of the Terra SEA, NHL agreed to purchase from the Terra Shareholders, and the Terra Shareholders agreed to sell to NHL, the Terra Purchased Shares on the closing date, in exchange for payment by NHL of the purchase price (the “Purchase Price”) of CAD$ 500,000 398,050 33.50 The Exchange closed on November 17, 2021. At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 91 100 11,883 91 In addition, the Company will issue 50,000 15.90 983,925 A summary of the purchase price allocation for Terra at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925 Share Exchange Agreement to Acquire 50.1 On March 1, 2022, the Company and NHL completed a Share Exchange Agreement (the “1285 SEA”) with 12858461 Canada Corp. (“1285”), a Canada federal corporation in the business of providing clinic-based physiotherapy and related ancillary services and products, and Prashant A. Jani, a Canadian citizen and sole shareholder of 1285 (the “1285 Shareholder”), to acquire 50.1 68,000 1,700 40.00 This acquisition was considered an acquisition of a business under ASC 805. A summary of the purchase price allocation for 1285 at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 602 Intangible assets 31,101 Minority interest (25,401 ) Purchase price $ 25,500 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500 Asset Purchase Agreement with Poling Taddeo Hovius Physiotherapy Professional Corp., operating as Fairway Physiotherapy and Sports Injury Clinic On March 1, 2022, the Company and NHL completed an Asset Purchase Agreement (the “PTHPC APA”) with Poling Taddeo Hovius Physiotherapy Professional Corp. (“PTHPC”), operating a clinic-based physiotherapy, rehabilitative, and related ancillary services and products business known as Fairway Physiotherapy and Sports Injury Clinic (“FAIR”), and Jason Taddeo, a Canadian citizen and the sole shareholder of PTHPC (the “PTHPC Shareholder”), Under the terms and conditions of the PTHPC APA, PTHPC agreed to sell, assign and transfer to NHL, free and clear of all encumbrances, other than permitted encumbrances, and NHL agreed to purchase from PTHPC all of PTHPC’s right, title and interest in and to all of its assets related to FAIR and the FAIR Business, with the exception of certain limited exclusions, and the rights, privileges, claims and properties of any kind whatsoever that are related thereto, whether owned or leased, real or personal, tangible or intangible, of every kind and description and wheresoever situated. Under the terms and conditions of the PTHPC APA, the purchase price is $ 627,000 15,675 40.00 This acquisition was considered an acquisition of a business under ASC 805. A summary of the purchase price allocation for PTHPC at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Intangible asset 151,686 Purchase price $ 235,125 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125 Membership Interest Purchase Agreement with Clinical Consultants International LLC On March 17, 2022, the Company entered into a Membership Interest Purchase Agreement (the “CCI Agreement”) by and among the Company, CCI, each of the members of CCI (the “CCI Members”), and Dr. Joseph Chalil as the representative of the CCI Members. Pursuant to the terms of the CCI Agreement, among other things, the CCI Members will sell and assign to the Company all of their membership interests of CCI, in exchange for a total of 80,000 100 80,000 This CCI Acquisition was accounted for as an asset acquisition, as substantially all of the fair value of the assets being acquired under the arrangement was concentrated in the customer relationships. Accordingly, the $ 1,704,000 1,701,814 A summary of the purchase price allocation for CCI at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Intangible asset 1,701,814 Purchase price $ 1,704,000 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Aug. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time to time incidental to the conduct of its business (including the matters described below). The Company recognizes liabilities for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in such matters, as well as potential ranges of possible losses (taking into consideration any insurance recoveries), based on a careful analysis of each matter with the assistance of outside legal counsel and, if applicable, other experts. Such matters included an action against one of the Company’s subsidiaries for settlement of outstanding legal fees relating to an unsuccessful transactions. Based on available information to date, the Company estimates that a resolution of these matters would result in a probable loss of at least $ 369,500 500,000 Given the uncertainty inherent in litigation and investigations, the Company does not believe it is possible to develop estimates of reasonably possible losses (or a range of possible losses) in excess of current accruals for such matters. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Segment Reporting

Segment Reporting	12 Months Ended
	Aug. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 18 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the years ended August 31, 2023 and 2022: Schedule of Segment Reporting Information 2023 2022 Years Ended August 31, 2023 2022 Sales Healthcare services $ 8,226,674 $ 8,397,857 Product Sales 4,335,645 3,336,899 Corporate 9,700 3,181 Sales $ 12,572,019 $ 11,737,937 Gross profit Healthcare services $ 2,998,315 $ 3,448,233 Product Sales 1,944,701 1,347,825 Corporate 9,699 3,180 Gross profit $ 4,952,715 $ 4,799,238 Loss from operations Healthcare services $ (413,670 ) $ (1,506,135 ) Product Sales (2,958,225 ) (4,940,559 ) Corporate (5,181,267 ) (18,579,983 ) Income (loss) from operations $ (8,553,162 ) $ (25,026,677 ) Depreciation and amortization Healthcare services $ 132,539 $ 141,529 Product Sales 1,052,406 1,337,324 Corporate 1,117,809 1,540,400 Depreciation and amortization $ 2,302,754 $ 3,019,253 Capital expenditures Healthcare services $ - $ - Product Sales 49,224 3,600 Corporate - - Capital expenditures $ 49,224 $ 3,600 Interest expenses Healthcare services $ 92,327 $ 76,255 Product Sales 55,441 962,480 Corporate 212,803 555,540 Interest expenses $ 360,571 $ 1,594,275 Net loss Healthcare services $ (496,970 ) $ (1,408,891 ) Product Sales (3,193,859 ) (7,305,571 ) Corporate (9,578,615 ) (24,330,716 ) Net loss $ (13,269,444 ) $ (33,045,178 ) Total assets Healthcare services $ 5,158,851 $ 5,917,403 Product Sales 17,993,652 19,595,269 Corporate 12,410,544 15,360,168 $ 35,563,047 $ 40,872,840 Accounts receivable Healthcare services $ 697,440 $ 585,492 Product Sales 765,388 419,417 Corporate 4,200 12,496 $ 1,467,028 $ 1,017,405 Intangible assets Healthcare services $ 120,163 $ 159,453 Product Sales 3,818,313 5,283,333 Corporate 12,280,063 13,397,832 $ 16,218,539 $ 18,840,619 Goodwill Healthcare services $ 520,821 $ 537,537 Product Sales 7,061,662 7,288,307 Corporate - - $ 7,582,483 $ 7,825,844

Subsequent Events

Subsequent Events	12 Months Ended
	Aug. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 19 – Subsequent Events September 2023 Mast Hill SPA On September 12, 2023, the Company entered into a securities purchase agreement (the “September 2023 Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 September 12, 2024 3,500,000 12 350,000 3,150,000 4.50 91.5 Pursuant to the terms of the September 2023 Mast Hill Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 12, 2023, (ii) $ 350,000 350,000 350,000 595,000 595,000 595,000 85 The Company may prepay the September 2023 Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Note) occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the September 2023 Mast Hill Note shall become immediately due and payable and the Company will pay to Mast Hill an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 Mast Hill SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 Mast Hill Note. Further, pursuant to the September 2023 Mast Hill SPA, the Company agreed to transfer its rights to the charges/mortgages evidenced by Instrument Nos. CE925256 (in the amount of CDN$ 1,600,000 1,800,000 1,772,045 The Company’s subsidiary, Acenzia Inc. (“Acenzia”), entered into a guaranty with Mast Hill on September 12, 2023. Acenzia guaranteed the repayment of the September 2023 Mast Hill Note and granted Mast Hill a security interest in Acenzia’s assets, including but not limited to, the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada. September 2023 FirstFire SPA & Note On September 18, 2023, the Company entered into a securities purchase agreement (the “September 2023 FirstFire SPA”) with FirstFire Global Opportunities Fund, L.P. (“FirstFire”), pursuant to which the Company issued an 12 September 18, 2024 277,778 12 27,778 250,000 4.50 91.5 Pursuant to the terms of the September 2023 FirstFire Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 18, 2023, (ii) $ 27,778 27,778 27,778 47,222 47,222 47,222 85 The Company may prepay the September 2023 FirstFire Note at any time prior to the date that an event of default occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the September 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 FirstFire SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 FirstFire Note. In addition to the beneficial ownership limitations provided in the September 2023 FirstFire Note, the sum of the number of shares of common stock that may be issued under the September 2023 FirstFire SPA and September 2023 FirstFire Note shall be limited to 480,156 Acenzia entered into a guaranty with FirstFire on September 18, 2023. Acenzia guaranteed the repayment of the September 2023 FirstFire Note and granted FirstFire a security interest in Acenzia’s assets, including but not limited to the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada, which is junior in priority to the security interest granted by Acenzia to FirstFire. Bylaws Amendment On September 27, 2023, the Company’s Board of Directors (the “Board”) adopted an amendment (the “Bylaws Amendment”) to the Company’s bylaws that had the effect of reducing the quorum at all meetings of the Company’s stockholders for the transaction of business, except as otherwise provided by statute or by the Company’s articles of incorporation, as amended, to one-third (33⅓%) of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy (the “Reduced Quorum Requirement”). The Company’s bylaws previously provided that the holders of a majority of the voting power of all outstanding shares of capital stock of the Company entitled to vote would constitute a quorum at all meetings of stockholders for the transaction of business. Blacksheep Master (Asset Transfer) Agreement On September 27, 2023, the Company entered into a Master (Asset Transfer) Agreement (the “Master Agreement”) by and between the Company and Blacksheep Trust (“Blacksheep”). Pursuant to the terms of the Master Agreement, Blacksheep agreed to transfer, on such dates as agreed to by the Company and Blacksheep, to the Company certain collateral equal to $ 1 The parties to the Master Agreement intend that the transfer of Collateral will be duly validated and authenticated by third-party audit procedures, said audit will allow for the transfer and monetization of the transferred Collateral, free and clear of any liens, claims or encumbrances, from Blacksheep to the Company and that the Collateral will not be a part of Blacksheep’s property for any purposes under state or federal law. Pursuant to the terms of the Master Agreement, Blacksheep will be entitled to an annual distribution of 10% of net profits as identified by an independent auditor based on the Company’s business activity resulting from the direct investment of any funds derived from the monetization of transferred Collateral. The Company has the right to the Collateral for no more than 15 years from the date of monetization, with the Company’s exclusive right to repatriate the Collateral to Blacksheep sooner without penalty. Blacksheep will be permitted one seat on the Company’s Board, which position will remain available for the term of the Collateral transfer or until the Collateral is repatriated to Blacksheep. Any draw against the monetization of the Collateral will require unanimous Board consent. The Master Agreement contains customary representations, warranties, and covenants of the Company and Blacksheep. 2023 Equity Incentive Plan On September 29, 2023, stockholders of the Company approved the 2023 Equity Incentive Plan. Reverse Stock Split The Company effectuated a 1-for-10 reverse stock split (the “Reverse Stock Split”) effective immediately after the close of trading on the Nasdaq Capital Market (“Nasdaq”) on November 6, 2023, and the Company’s common stock began trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023. As a result of the Reverse Stock Split, every 10 pre-split shares of common stock outstanding became one share of common stock, with fractional shares rounded up to the next higher whole share. The Reverse Stock Split did not affect the number of authorized shares of common stock, the par value of the common stock, or modify any rights or preferences of shares of the Company’s common stock Purchase and Sale Agreement – Ophir Collection On November 21, 2023, the Company entered into a Purchase and Sale Agreement (“Ophir Agreement”) between the Company and Blake Alsbrook, solely in his capacity as Court-appointed successor receiver (the “Successor Receiver”) in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California (the “Court”) Case No. 2:19-cv-04299 VAP (JPRx) (the “Action”). Pursuant to the terms of the Ophir Agreement, the Company agreed to purchase, and the Successor Receiver agreed to sell to the Company, the Ophir Collection (as hereinafter defined), subject to the contingencies outlined in the Ophir Agreement, including Court approval, which approval was received on December 1, 2023. The Ophir Agreement was effective upon execution by both parties; however, the Ophir Agreement was subject to approval by the Court. Pursuant to the Court’s July 2, 2019 order in the Action, as modified by the Court’s February 25, 2022 order in the Action, the Successor Receiver has possession of and right to sell a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection”. Together, the Court’s July 2, 2019 order appointing the original receiver, the Court’s December 3, 2019, order appointing the Successor Receiver, and the Court’s February 25, 2022, order are referred to collectively as the “Receivership Orders.” The Receivership Orders authorized the Successor Receiver to take sole custody, possession, and control of the Ophir Collection and to sell, assign, transfer, convey and deliver title and rights in and to the Ophir Collection subject to the approval of the Court to protect the interests of certain identified creditors. Within two business days following the Company’s execution of the Ophir Agreement, the Company was required to, and did, deposit $ 25,000 Pursuant to the terms of the Ophir Agreement, the Company agreed to pay $ 60,000,000 (i) The Company has the right, at all times after November 21, 2023, to conduct a full and unfettered inspection of the Ophir Collection. While the Company has the right to inspect the Ophir Collection prior to closing, the Company’s inspection will not be a contingency to closing and the inability of the Company to inspect (or the Company’s decision not to inspect) the Ophir Collection prior to closing will not delay or prevent closing. (ii) After the Successor Receiver obtains Court approval of the Ophir Agreement, the Company will cause $ 59,975,000 60,000,000 (iii) Within one business day thereafter, the Successor Receiver will assign, transfer, convey and deliver free and clear title and interest in and to, and possession of, the Ophir Collection to the Company. As a result of entry into the Ophir Agreement, the Company no longer intends to pursue a transaction with SwagCheck Inc. (“SWAG”). The Share Purchase Agreement, dated as of December 23, 2022, by and among the Company, SWAG and all SWAG shareholders, as amended, previously terminated pursuant to its terms. Nasdaq Notification – Compliance of Minimum Bid Price Requirement On November 22, 2023, the Company received notice from Nasdaq informing the Company that it has regained compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing on Nasdaq. As previously disclosed, on November 21, 2022, Nasdaq notified the Company that its common stock failed to maintain a minimum bid price of $ 1.00 1.00 1.00 Clawback Policy On November 22, 2023, the Company’s Board of Directors adopted a Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-for-performance philosophy and to comply with applicable law by providing for the reasonably prompt recovery of certain incentive-based compensation received by executive officers in the event of an accounting restatement. The Policy is intended to comply with, and will be interpreted in a manner consistent with, Section 10D of the Exchange Act, with Exchange Act Rule 10D-1 and with the Nasdaq listing standards. Pursuant to the Policy, if the Company is required to prepare an accounting restatement due to the material noncompliance by the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an “Accounting Restatement”), then the Compensation Committee must determine the Excess Compensation (as hereinafter defined), if any, that must be recovered. The Company’s obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed. The Company must recover Excess Compensation reasonably promptly and executive officers are required to repay Excess Compensation to the Company, subject to the terms of the Policy. The Policy applies to certain incentive-based compensation that is received on or after November 1, 2023, during the three completed fiscal years immediately preceding the Accounting Restatement determination date, as provided in the Policy (the “Covered Period”) while the Company has a class of securities listed on a national securities exchange. The incentive-based compensation is considered “Clawback Eligible Incentive-Based Compensation” if the incentive-based compensation is received by a person after such person became an executive officer and the person served as an executive officer at any time during the performance period to which the incentive-based compensation applies. The “Excess Compensation” that is subject to recovery under the Policy is the amount of Clawback Eligible Incentive-Based Compensation that exceeds the amount of Clawback Eligible Incentive-Based Compensation that otherwise would have been received had such Clawback Eligible Incentive-Based Compensation been determined based on the restated amounts (this is referred to in the listing standards as “erroneously awarded incentive-based compensation”). Share Issuance in Exchange for Certain NHL Non-Voting Special Shares Subsequent to the fiscal year ended August 31, 2023, the Company issued 737,642 Share Issuances in Connection with S-1 Warrant Exercises Subsequent to the fiscal year ended August 31, 2023, the Company issued 240,400 Stock Issuance – Consulting Agreements Subsequent to the fiscal year 2023 period end, the Company issued 375,000 Stock Issuance – Mast Hill Cashless Warrant Exercise On September 18, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,567 On October 23, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 445,000 138,703 Stock Issuance – FirstFire Cashless Warrant Exercise On October 12, 2023, FirstFire fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,532

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.
Noncontrolling Interest	Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and comprehensive loss.
Cash Equivalents	Cash Equivalents For the purpose of the consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2023 and 2022, the allowance for uncollectible accounts receivable was $ 864,215 992,329
Inventory	Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of August 31, 2023 and 2022, the Company’s allowance for slow moving or obsolete inventory was $ nil 1,027,670
Other Receivables	Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the years ended August 31, 2023 and 2022, the Company wrote off $ nil 299,672 225,924 73,748
Property and Equipment	Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Leases	Leases The Company applies the provisions of ASC Topic 842, Leases
Long-Lived Assets	Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no
Intangible Assets	Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2023 and 2022, the Company believes there was $ nil 14,083,531
Right-of-use Assets	Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $ 1,357,043 no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Ending balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of August 31, 2023 and 2022, respectively, the Company did not identify any financial assets and liabilities required to be presented on the consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs.
Derivative Financial Instruments	Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.
Revenue Recognition	Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ASU No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying consolidated balance sheets. Sales returns and allowances were insignificant for the years ended August 31, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 1,777,678 1,060,950 581,715 91,138 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.
Foreign Currency Transactions and Comprehensive Income	Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation losses of $ 922,609 431,605
Consolidated Statements of Cash Flows	Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.
Segment Reporting	Segment Reporting ASC Topic 280, Segment Reporting two
Reclassifications	Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In March 2020, the FASB issued ASU No. 2020-04 providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020, could be applied through December 31, 2022. In December 2022, the FASB issued No 2022-06 extending the sunset date of the relief provided under ASU No. 2020-04 to December 31, 2024. The ASU has not impacted these consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2024. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which is intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The guidance allows for either full retrospective adoption or modified retrospective adoption. The ASU is effective for the fiscal years beginning after December 15, 2023 and early adoption is permitted. The Company is currently evaluating the effect of this ASU on the Company’s consolidated financial statements and related disclosures. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	12 Months Ended
	Aug. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	Schedule of Foreign Currency Translation, Exchange Rate Used August 31, 2023 August 31, 2022 Period end: CAD to USD exchange rate $ 0.7390 $ 0.7627 Average period: CAD to USD exchange rate $ 0.7426 $ 0.7864

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2023
Accounting Policies [Abstract]
Schedule of Estimated Useful lives of Assets	Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Schedule of Intangible Assets Amortized Estimated Useful Lives	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7
Schedule of Changes in Goodwill	Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Ending balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Aug. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at August 31, 2023 and 2022 consisted of the following: Schedule of Inventory 2023 2022 Raw materials $ 388,391 $ 1,259,954 Work in process 81,696 139,333 Finished Goods 636,896 507,416 Inventory Gross 1,106,983 1,906,703 Allowance for slow moving and obsolete inventory - (1,027,670 ) Inventory, net $ 1,106,983 $ 879,033

Accounts Receivables, net (Tabl

Accounts Receivables, net (Tables)	12 Months Ended
	Aug. 31, 2023
Receivables [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivables, net at August 31, 2023 and 2022 consisted of the following: Schedule of Accounts Receivable, Net 2023 2022 Trade receivables $ 2,223,243 $ 1,829,475 Amounts earned but not billed 108,000 180,259 Accounts receivables gross 2,331,243 2,009,734 Allowance for doubtful accounts (864,215 ) (992,329 ) Accounts receivable, net $ 1,467,028 $ 1,017,405

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Aug. 31, 2023
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at August 31, 2023 and 2022 consisted of the following: Schedule of Other Receivables 2023 2022 Advance to corporation; accrues interest at 12 January 31, 2024 73,900 76,272 Advance to corporation; accrues interest at 12 February 1, 2024 534,386 551,536 Advance to corporation; accrues interest at 10 February 1, 2024 443,298 457,527 Total other receivables 1,051,584 1,085,335 Current portion (1,051,584 ) (1,085,335 ) Long-term portion $ - $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Aug. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at August 31, 2023 and 2022 consisted of the following: Schedule of Property and Equipment 2023 2022 Land $ 443,400 $ 457,631 Building 3,325,500 3,432,232 Leasehold improvements 841,371 868,375 Clinical equipment 1,916,681 1,927,639 Computer equipment 33,504 34,579 Office equipment 44,502 45,406 Furniture and fixtures 38,289 39,518 Property and Equipment gross 6,643,247 6,805,380 Accumulated depreciation (1,253,209 ) (1,004,732 ) Total $ 5,390,038 $ 5,800,648

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Aug. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at August 31, 2023 and 2022 consisted of the following: Schedule of Intangible Assets 2023 2022 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,497,746 8,059,386 Customer relationships 2,291,058 2,320,154 Brand names 1,928,421 1,990,314 Finite lived intangible assets, gross 23,290,546 23,943,175 Accumulated amortization (7,072,007 ) (5,102,556 ) Total $ 16,218,539 $ 18,840,619
Schedule of Expected Amortization Expense of intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Years Ending August 31, 2024 $ 2,006,623 2025 1,944,426 2026 1,494,169 2027 1,288,217 2028 848,582 Thereafter 8,636,522 Total $ 16,218,539

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Aug. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at August 31, 2023 and 2022 consisted of the following: Schedule of Accrued Expenses 2023 2022 Accrued liabilities $ 961,897 $ 884,024 Accrued payroll 236,218 195,214 Unearned revenue 35,434 36,887 Accrued expense $ 1,233,549 $ 1,116,125

Government Loans and Note Pay_2

Government Loans and Note Payable and Government Subsidy (Tables)	12 Months Ended
	Aug. 31, 2023
Government Loans And Note Payable And Government Subsidy
Schedule of Governmental Loans and Note Payable	Governmental loans and note payable at August 31, 2023 and 2022 consisted of the following: Schedule of Governmental Loans and Note Payable 2023 2022 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A) 88,680 91,526 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,693 29,614 Note payable received May 25, 2023 accruing interest at 18 73,900 - Note payable received May 10, 2023 accruing interest at 15 110,850 - Total government loans and notes payable 342,443 161,460 Less current portion (277,405 ) - Long-term portion $ 65,038 $ 161,460 (A) The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,560
Schedule of Future Maturities Outstanding of government Loans and Notes Payable	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Years Ending August 31, 2024 $ 277,405 2025 6,408 2026 6,557 2027 6,714 2028 6,878 Thereafter 38,481 Total $ 342,443

Leases (Tables)

Leases (Tables)	12 Months Ended
	Aug. 31, 2023
Leases
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2023 and 2022: Schedule of Lease Related Assets and Liabilities 2023 2022 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,983,898 $ 2,673,934 Total lease assets $ 1,983,898 $ 2,673,934 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 415,392 $ 582,088 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,693,577 2,185,329 Total lease liability $ 2,108,969 $ 2,767,417
Schedule of Lease Obligations	Lease obligations at August 31, 2023 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2024 $ 579,780 2025 510,085 2026 509,330 2027 472,291 2028 254,187 Thereafter 300,769 Total payments 2,626,442 Amount representing interest (517,473 ) Lease obligation, net 2,108,969 Less lease obligation, current portion (415,392 ) Lease obligation, long-term portion $ 1,693,577
Schedule of Finance Leases	The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2023 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (209,457 ) Net book value $ -
Schedule of Future Minimum Lease Payments	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2024 $ 11,810 Total payments 11,810 Amount representing interest (66 ) Lease obligation, net 11,744 Less lease obligation, current portion (11,744 ) Lease obligation, long-term portion $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	12 Months Ended
	Aug. 31, 2023
Equity [Abstract]
Schedule of Stock Option Activity	The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 184,960 22.90 3.14 $ 218,240 Granted 36,946 14.60 3.80 Expired - Forfeited (5,483 ) Exercised - Outstanding, August 31, 2022 216,423 21.50 2.53 $ 140,577 Granted 200,000 1.32 5.75 Expired (45,000 ) Exercised - Outstanding, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000 Exercisable, August 31, 2023 371,423 $ 11.44 3.98 $ 16,000
Schedule of Options Outstanding and Exercisable	The exercise price for stock options outstanding and exercisable at August 31, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423
Schedule of Fair Value of Options Granted by Using Valuation Assumptions	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the year ended August 31, 2023 and 2022: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2023 2022 Risk-free interest rate 3.74 % 0.93 3.01 % Expected life of the options 6 2.5 Expected volatility 254 % 267 281 % Expected dividend yield 0 % 0 %
Schedule of Warrant Activity	The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 238,805 33.50 5.12 $ - Granted 605,721 20.50 3.25 Forfeited - Exercised - Outstanding, August 31, 2022 844,526 24.18 3.50 $ - Granted 1,077,661 1.39 3.51 Forfeited - Exercised (1,115,933 ) Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Exercisable, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960
Schedule of Warrants Outstanding	The exercise price for warrants outstanding at August 31, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 267,400 1.00 277,661 2.50 806,254

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Aug. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective and Statutory Income Tax Rates	A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2023 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (3,515,747 ) $ (9,698,805 ) $ (13,214,552 ) Expected income tax benefit (931,672 ) -26.5 % (2,618,677 ) -27.0 % (3,550,349 ) Stock based compensation - 0.0 % 233,800 9.0 % 233,800 Change in valuation allowance 931,672 26.5 % 2,384,877 18.0 % 3,316,549 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2022 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (8,105,151 ) $ (24,744,064 ) $ (32,849,215 ) Expected income tax benefit (2,147,864 ) -26.5 % (6,680,897 ) -27.0 % (8,828,761 ) Stock based compensation - 0.0 % 474,239 17.4 % 474,239 Change in valuation allowance 2,147,864 26.5 % 6,206,658 9.6 % 8,354,522 $ - 0.0 % $ - 0.0 % $ - 0.0 %
Schedule of the Deferred Tax Assets	At August 31, 2023 and 2022, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2023 2022 Deferred tax asset: Net operating loss carryforwards $ 15,839,947 $ 12,523,398 Total deferred tax asset 15,839,947 12,523,398 Less: valuation allowance (15,839,947 ) (12,523,398 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,400,499 ) (1,445,448 ) Total deferred tax liability (1,400,499 ) (1,445,448 ) Net deferred tax liability $ (1,400,499 ) $ (1,445,448 )

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Aug. 31, 2023
Terragenx [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 602 Intangible assets 31,101 Minority interest (25,401 ) Purchase price $ 25,500
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Intangible asset 151,686 Purchase price $ 235,125
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Intangible asset 1,701,814 Purchase price $ 1,704,000
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Aug. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following tables summarize the Company’s segment information for the years ended August 31, 2023 and 2022: Schedule of Segment Reporting Information 2023 2022 Years Ended August 31, 2023 2022 Sales Healthcare services $ 8,226,674 $ 8,397,857 Product Sales 4,335,645 3,336,899 Corporate 9,700 3,181 Sales $ 12,572,019 $ 11,737,937 Gross profit Healthcare services $ 2,998,315 $ 3,448,233 Product Sales 1,944,701 1,347,825 Corporate 9,699 3,180 Gross profit $ 4,952,715 $ 4,799,238 Loss from operations Healthcare services $ (413,670 ) $ (1,506,135 ) Product Sales (2,958,225 ) (4,940,559 ) Corporate (5,181,267 ) (18,579,983 ) Income (loss) from operations $ (8,553,162 ) $ (25,026,677 ) Depreciation and amortization Healthcare services $ 132,539 $ 141,529 Product Sales 1,052,406 1,337,324 Corporate 1,117,809 1,540,400 Depreciation and amortization $ 2,302,754 $ 3,019,253 Capital expenditures Healthcare services $ - $ - Product Sales 49,224 3,600 Corporate - - Capital expenditures $ 49,224 $ 3,600 Interest expenses Healthcare services $ 92,327 $ 76,255 Product Sales 55,441 962,480 Corporate 212,803 555,540 Interest expenses $ 360,571 $ 1,594,275 Net loss Healthcare services $ (496,970 ) $ (1,408,891 ) Product Sales (3,193,859 ) (7,305,571 ) Corporate (9,578,615 ) (24,330,716 ) Net loss $ (13,269,444 ) $ (33,045,178 ) Total assets Healthcare services $ 5,158,851 $ 5,917,403 Product Sales 17,993,652 19,595,269 Corporate 12,410,544 15,360,168 $ 35,563,047 $ 40,872,840 Accounts receivable Healthcare services $ 697,440 $ 585,492 Product Sales 765,388 419,417 Corporate 4,200 12,496 $ 1,467,028 $ 1,017,405 Intangible assets Healthcare services $ 120,163 $ 159,453 Product Sales 3,818,313 5,283,333 Corporate 12,280,063 13,397,832 $ 16,218,539 $ 18,840,619 Goodwill Healthcare services $ 520,821 $ 537,537 Product Sales 7,061,662 7,288,307 Corporate - - $ 7,582,483 $ 7,825,844

Schedule of Foreign Currency Tr

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	Aug. 31, 2023	Aug. 31, 2022
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7390	0.7627
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7426	0.7864

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)								12 Months Ended
	Nov. 07, 2023	Nov. 06, 2023	Jul. 20, 2022	Jun. 29, 2022	May 11, 2022	May 09, 2017	Apr. 25, 2017	Aug. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction								$ 1,704,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1-for-10 reverse stock split	1-for-10 reverse stock split (the “Reverse Stock Split”) effective immediately after the close of trading on the Nasdaq Capital Market (“Nasdaq”) on November 6, 2023, and the Company’s common stock began trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023. As a result of the Reverse Stock Split, every 10 pre-split shares of common stock outstanding became one share of common stock, with fractional shares rounded up to the next higher whole share. The Reverse Stock Split did not affect the number of authorized shares of common stock, the par value of the common stock, or modify any rights or preferences of shares of the Company’s common stock
Parent Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction						$ 6,904
Share Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares			15,896	30,000	22,500
Share Exchange Agreement [Member] | NHL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares							1,677,974
Percentage of common stock issued and outstanding							85%

Schedule of Estimated Useful li

Schedule of Estimated Useful lives of Assets (Details)	Aug. 31, 2023
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	Aug. 31, 2023
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years

Schedule of Changes in Goodwill

Schedule of Changes in Goodwill (Details) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Beginning balance	$ 7,825,844	$ 9,488,848
Goodwill acquired with purchase of business		602
Impairment of goodwill		(1,357,043)
Foreign currency translation adjustment	(243,361)	(306,563)
Ending balance	7,582,483	7,825,844
APKA Health, Inc. [Member]
Beginning balance	190,678	197,925
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(5,928)	(7,247)
Ending balance	184,750	190,678
Executive Fitness Leaders [Member]
Beginning balance	125,088	129,839
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(3,892)	(4,751)
Ending balance	121,196	125,088
Rockland [Member]
Beginning balance	221,188	229,593
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(6,878)	(8,405)
Ending balance	214,310	221,188
Acenzia Inc [Member]
Beginning balance	7,288,307	8,931,491
Goodwill acquired with purchase of business
Impairment of goodwill		(1,357,043)
Foreign currency translation adjustment	(226,645)	(286,141)
Ending balance	7,061,662	7,288,307
12858461 Canada Corp [Member]
Beginning balance	583
Goodwill acquired with purchase of business		602
Impairment of goodwill
Foreign currency translation adjustment	(18)	(19)
Ending balance	$ 565	$ 583

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Aug. 31, 2023 USD ($) Integer shares	Aug. 31, 2022 USD ($) shares
Allowance for uncollectible accounts receivable	$ 864,215	$ 992,329
Inventory		1,027,670
Other receivable written off		299,672
Other receivable prinicipal amount	225,924
Other receivable accrued interest	73,748
Impairment of long-lived assets	0	0
Impairment of intangible assets		14,083,531
Contract lease term	12 months
Goodwill impairment charge		1,357,043
Foreign currency translation gain (loss)	$ 922,609	$ 431,605
Number of reportable segments | Integer	2
Common Stock [Member]
Debt conversion, converted instrument, shares issued | shares	581,715
Common Stock To Be Issued [Member]
Debt conversion, converted instrument, shares issued | shares	91,138
Options/Warrants Outstanding [Member]
Potentially dilutive common stock options and warrants outstanding, shares | shares	1,777,678	1,060,950
Terragenx Inc [Member]
Equity method investment, ownership percentage	91%
12858461 Canada Corp [Member]
Equity method investment, ownership percentage	50.10%
Novo Healthnet Kemptville Centre Inc [Member]
Equity method investment, ownership percentage	80%
Novo Earth Therapeutics Inc [Member]
Equity method investment, ownership percentage	70%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
6% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	6%	6%
13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	13.75%	13.75%
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 533,001	$ 478,897
Debentures, related parties	916,824	946,250
Related Party [Member] | Non-Interest Bearing [Member]
Related Party Transaction [Line Items]
Due to related parties	451,137	394,405
Related Party [Member] | 6% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties	21,267	21,949
Related Party [Member] | 13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 60,597	$ 62,543

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 388,391	$ 1,259,954
Work in process	81,696	139,333
Finished Goods	636,896	507,416
Inventory Gross	1,106,983	1,906,703
Allowance for slow moving and obsolete inventory		(1,027,670)
Inventory, net	$ 1,106,983	$ 879,033

Schedule of Accounts Receivable

Schedule of Accounts Receivable, Net (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Receivables [Abstract]
Trade receivables	$ 2,223,243	$ 1,829,475
Amounts earned but not billed	108,000	180,259
Accounts receivables gross	2,331,243	2,009,734
Allowance for doubtful accounts	(864,215)	(992,329)
Accounts receivable, net	$ 1,467,028	$ 1,017,405

Schedule of Other Receivables (

Schedule of Other Receivables (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,051,584	$ 1,085,335
Current portion	(1,051,584)	(1,085,335)
Long-term portion
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	73,900	76,272
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	534,386	551,536
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 443,298	$ 457,527

Schedule of Other Receivables_2

Schedule of Other Receivables (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Jan. 31, 2024	Jan. 31, 2024
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 6,643,247	$ 6,805,380
Accumulated depreciation	(1,253,209)	(1,004,732)
Total	5,390,038	5,800,648
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	443,400	457,631
Building [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	3,325,500	3,432,232
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	841,371	868,375
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	1,916,681	1,927,639
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	33,504	34,579
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	44,502	45,406
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 38,289	$ 39,518

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 292,041	$ 323,040

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 23,290,546	$ 23,943,175
Accumulated amortization	(7,072,007)	(5,102,556)
Total	16,218,539	18,840,619
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	11,573,321	11,573,321
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	7,497,746	8,059,386
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	2,291,058	2,320,154
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 1,928,421	$ 1,990,314

Schedule of Expected Amortizati

Schedule of Expected Amortization Expense of intangible Assets (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 2,006,623
2025	1,944,426
2026	1,494,169
2027	1,288,217
2028	848,582
Thereafter	8,636,522
Total	$ 16,218,539	$ 18,840,619

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)								12 Months Ended
	Mar. 06, 2020 USD ($) shares	Mar. 06, 2020 CAD ($) shares	Dec. 17, 2019 USD ($) shares	Feb. 26, 2019 USD ($) shares	Feb. 26, 2019 CAD ($) shares	Jan. 30, 2019 USD ($) shares	Jan. 07, 2019	Aug. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Mar. 17, 2021 USD ($)	Mar. 09, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets								$ 2,010,713	$ 2,696,213
Joint Venture Agreement [Member] | Kainai [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage joint venture description							Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai.
Intangible asset, useful life amortized over term							50 years
Number of restricted shares of common stock | shares						120,000
Number of restricted shares of common stock, value						$ 21,600,000
Payments to acquire land held for use									10,026,679
Asset Purchase Agreement [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock | shares			80,000
Number of restricted shares of common stock, value			$ 5,248,000
Payments to acquire land held for use									1,858,179
Software License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized computer software impairment shares | shares				4,000	4,000
Software License Agreement [Member] | Cloud DX, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock | shares				45,835	45,835
Number of restricted shares of common stock, value				$ 758,567	$ 1,000,000
Payments to acquire software license				$ 189,642	$ 250,000
Perpetual Software License Agreement [Member] | Cloud DX, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock | shares	4,656	4,656
Payments to acquire software license	$ 186,231	$ 250,000
Cloud DX Amendment [Member] | Novo Healthnet Limited, Inc [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock | shares	5,000	5,000
Payments to acquire software license	$ 200,000
Cloud DX Amendment [Member] | Pro-Dip, LLC [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired									52,752		$ 455,752
Cloud DX Amendment [Member] | Acenzia Inc [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											2,875,000
Cloud DX Amendment [Member] | Acenzia Inc [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											806,000
Cloud DX Amendment [Member] | Acenzia Inc [Member] | Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											2,115,000
Cloud DX Amendment [Member] | Terragenx Inc [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											1,179,361
Cloud DX Amendment [Member] | 12858461 Canada Corp [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											31,101
Cloud DX Amendment [Member] | Poling Taddeo Hovius Physiotherapy Professional Corp [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired											151,686
Cloud DX Amendment [Member] | Clinical Consultants International LLC [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangibles assets acquired									$ 317,314	$ 1,701,814	$ 1,701,814

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Payables and Accruals [Abstract]
Accrued liabilities	$ 961,897	$ 884,024
Accrued payroll	236,218	195,214
Unearned revenue	35,434	36,887
Accrued expense	$ 1,233,549	$ 1,116,125

Schedule of Governmental Loans

Schedule of Governmental Loans and Note Payable (Details) - USD ($)		Aug. 31, 2023	Aug. 31, 2022
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 342,443	$ 161,460
Less current portion		(277,405)
Long-term portion		65,038	161,460
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable	[1]	88,680	91,526
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		40,320	40,320
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		28,693	29,614
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		73,900
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 110,850
[1]The Government of Canada launched the Canada Emergency Business Account (“CEBA”) loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained a CAD$ 80,000 59,120 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,560

Schedule of Governmental Loan_2

Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)	12 Months Ended
	Aug. 31, 2023 USD ($)	Aug. 31, 2023 CAD ($)	Aug. 31, 2022 USD ($)	Aug. 31, 2023 CAD ($)
Short-Term Debt [Line Items]
Default in repayment rate	75%	75%
Interest rate during fixed rate	5%			5%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jan. 18, 2024	Jan. 18, 2024
Debt description	If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply	If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply
Forgiveness percentage	25%	25%
Canada Emergency Business Account Loan [Member] | Terragenx [Member]
Short-Term Debt [Line Items]
Notes Payable			$ 29,560	$ 60,000
Repayment of debt		$ 20,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period	3.75%	3.75%	3.75%
Periodic payment	$ 190		$ 190
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period	4.53%	4.53%	4.53%
Periodic payment	$ 4,000		$ 4,000
Debt instrument, maturity date	Dec. 02, 2028	Dec. 02, 2028	Dec. 02, 2028
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period	18%	18%
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period	15%	15%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 59,120			$ 80,000

Schedule of Future Maturities O

Schedule of Future Maturities Outstanding of government Loans and Notes Payable (Details)	Aug. 31, 2023 USD ($)
Government Loans And Note Payable And Government Subsidy
2024	$ 277,405
2025	6,408
2026	6,557
2027	6,714
2028	6,878
Thereafter	38,481
Total	$ 342,443

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)																																			12 Months Ended
	Aug. 12, 2024 USD ($)	Jul. 12, 2024 USD ($)	Jun. 12, 2024 USD ($)	May 12, 2024 USD ($)	Apr. 20, 2024 USD ($)	Apr. 12, 2024 USD ($)	Mar. 20, 2024 USD ($)	Mar. 12, 2024 USD ($)	Feb. 21, 2024 USD ($)	Feb. 20, 2024 USD ($)	Jan. 21, 2024 USD ($)	Jan. 20, 2024 USD ($)	Dec. 23, 2023 USD ($)	Dec. 21, 2023 USD ($)	Dec. 20, 2023 USD ($)	Nov. 23, 2023 USD ($)	Nov. 21, 2023 USD ($)	Oct. 23, 2023 USD ($)	Oct. 21, 2023 USD ($)	Sep. 23, 2023 USD ($)	Sep. 21, 2023 USD ($)	Aug. 24, 2023 USD ($)	Aug. 23, 2023 USD ($)	Aug. 21, 2023 USD ($) shares	Jun. 20, 2023 USD ($) $ / shares shares	Jun. 20, 2023 USD ($) $ / shares shares	May 20, 2023 USD ($)	Mar. 21, 2023 USD ($) $ / shares shares	Feb. 23, 2023 USD ($) $ / shares shares	Jan. 23, 2023 USD ($)	Nov. 14, 2022 USD ($)	Jun. 01, 2022 USD ($)	Dec. 14, 2021 USD ($) $ / shares shares	Nov. 17, 2021 USD ($) $ / shares shares	Aug. 31, 2023 USD ($) shares	Aug. 31, 2022 USD ($)	Jul. 20, 2023 USD ($)	Nov. 21, 2022 $ / shares
Debt face amount																																		$ 1,875,000
Convertible notes payable, note holders issued warrants to purchase total, shares | shares																																		22,388
Estimated value warrants																																		$ 351,240
Discount on convertable note and additional paid in capital																																		295,824
Loan fees																																		$ 90,000
Debt amortized discount																																			$ 4,757,121	$ 5,973,973
Share price | $ / shares																																		$ 33.50
Redemption of warrants description																																		The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $351,240 and was determined using the Black-Scholes option pricing model with the following assumptions:
Convertible notes payable																																		$ 1,579,176
Original issue discount																																		$ 375,000
Convertible notes payable																																			558,668	9,099,654
Common stock issuable upon exercise																						$ 580,778													$ 9,968,140	1,272,994
Stock issued during period, shares, new issues | shares																																			400,000
Mast Hill Securities Purchase Agreement [Member]
Debt face amount																									$ 445,000	$ 445,000			$ 573,000
Maturity date																										Jun. 20, 2024			Feb. 23, 2024
Debt conversion price | $ / shares																									$ 1.75	$ 1.75			$ 1.75
Exercise price of warrants or rights | $ / shares																									$ 2.50	$ 2.50			$ 2.50
Estimated value warrants																													$ 86,327
Debt instrument, unamortized discount																													57,300
Loan fees																									$ 39,904	$ 39,904			70,465
Debt amortized discount																													$ 297,055						297,055
Accrued interest																																			$ 6,028
Debt converted into common stock | shares																																			522,777
Debt instrument aggregate principal amount																																			$ 573,000
Share price | $ / shares																									$ 1.535	$ 1.535
Original issue discount																									$ 44,500	$ 44,500
Convertible notes payable																								$ 4,535													$ 4,243
Debt instrument, interest rate, effective percentage																									12%	12%			12%
Class of warrant or right, number of shares | shares																									1,772,045	1,772,045			2,772,045
Payment of amortization																							$ 57,300		$ 445,000		$ 77,661			$ 100,000
Percentage of stock price trigger																										85%			85%
Administrative fees expense																										$ 750			$ 750
Variable interest, percentage rate																									125%	125%			125%
Number of restricted shares of common stock | shares																													95,500
Percentage of issued and outstanding common stock																													19.99%
Other fees																																			1,750
Debt instrument, effective conversion price | $ / shares																									$ 1.150	$ 1.150
Beneficial conversion feature																									$ 97,978
Payments for repurchase of warrants																										$ 400,500
Common stock issuable upon exercise																									445,000
Estimated value of the warrants																									$ 77,856
Stock issued during period, shares, new issues | shares																										74,167
Mast Hill Securities Purchase Agreement [Member] | Forecast [Member]
Payment of amortization	$ 595,000	$ 595,000	$ 595,000	$ 350,000	$ 77,661	$ 350,000	$ 77,661	$ 350,000		$ 44,500		$ 44,500	$ 100,000		$ 445,000	$ 100,000		$ 57,300		$ 57,300
Mast Hill Securities Purchase Agreement [Member] | Maximum [Member]
Class of warrant or right, number of shares | shares																									77,662	77,662			100,000
Variable interest, percentage rate																									16%	16%			16%
Mast Hill Note and Mast Hill Warrant [Member]
Debt instrumment converted amount																													$ 515,700
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																												$ 573,000
Maturity date																												Mar. 21, 2024
Debt conversion price | $ / shares																												$ 1.75
Exercise price of warrants or rights | $ / shares																												$ 2.50
Estimated value warrants																												$ 93,811
Debt instrument, unamortized discount																												57,300							190,209
Loan fees																												35,628
Debt amortized discount																												$ 342,938							152,729
Share price | $ / shares																												$ 1.390
Debt instrument, interest rate, effective percentage																												12%
Class of warrant or right, number of shares | shares																												1,000,000
Percentage of stock price trigger																												85%
Administrative fees expense																												$ 750
Variable interest, percentage rate																												125%
Number of restricted shares of common stock | shares																												95,500
Debt instrument, effective conversion price | $ / shares																												$ 1.188
Beneficial conversion feature																												$ 66,068
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | Forecast [Member]
Payment of amortization									$ 100,000		$ 100,000			$ 100,000			$ 57,300		$ 57,300		$ 57,300
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] | Maximum [Member]
Class of warrant or right, number of shares | shares																												100,000
Variable interest, percentage rate																												16%
First Fire Note and First Fire Warrant [Member]
Debt instrumment converted amount																												$ 515,700
Terragenx Inc [Member]
Ownership percentage																																		91%
Terragenx Inc [Member] | Promissory Notes Payment [Member]
Convertible notes payable																																$ 1,875,000
Notes payable																																948,874
Terragenx Inc [Member] | Promissory Notes Payment and Extension [Member]
Convertible notes payable																																1,875,000
Notes payable																																937,500
Convertible notes payable																																$ 192,188
Maturity date																																Nov. 29, 2022
Jefferson Street Capital [Member]
Debt converted into common stock | shares																								236,511
Convertible notes payable																																$ 1,875,000
Notes payable																																$ 186,719
Maturity date																																Nov. 29, 2022
Warrant [Member]
Debt face amount																																	$ 5,257,466
Estimated value of the warrants																																			$ 1,137,959
Warrant [Member] | Mast Hill Securities Purchase Agreement [Member]
Debt face amount																									$ 77,856	$ 77,856			86,327
Warrant [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																												93,811
Common Stock [Member]
Debt converted into common stock | shares																																			581,715
Share price | $ / shares																																						$ 1
Other fees																																			$ 140,000
Common stock issuable upon exercise																																			$ 10,178	64
Stock issued during period, shares, new issues | shares																																			400,000
Common Stock [Member] | Maximum [Member]
Share price | $ / shares																																						$ 1
Common Stock [Member] | Mast Hill Securities Purchase Agreement [Member]
Debt face amount																									74,793	74,793			82,963
Common Stock [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																												90,132
Convertible Debt [Member]
Debt face amount																																	$ 11,409,200
Convertible Debt [Member] | Mast Hill Securities Purchase Agreement [Member]
Debt face amount																									$ 292,351	$ 292,351			$ 403,710
Convertible Debt [Member] | First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																												$ 389,057
Convertible Notes [Member]
Debt instrument, unamortized discount																																				0
Debt amortized discount																																		$ 760,824		760,824
Debt description																															(i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion.
Measurement Input, Expected Term [Member]
Warrants and rights outstanding, term																									5 years	5 years		5 years	5 years				4 years	3 years
Derivative liability, measurement input, term																															6 months 29 days
Measurement Input, Price Volatility [Member]
Warrants measurement input percentage																									251	251		251	252				275	300
Derivative liability measurement input percentage																															148.20
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input percentage																									0	0		0	0				0	0
Derivative liability measurement input percentage																															0
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input percentage																									3.96	3.96		3.73	4.09				1.23	0.85
Derivative liability measurement input percentage																															4.55
Two Convertible Notes [Member]
Debt face amount																																	$ 16,666,666		$ 8,396,666
Interest Rate, Stated Percentage																																	5%
Maturity date																																	Jun. 14, 2023
Debt conversion price | $ / shares																																	$ 20
Convertible notes payable, note holders issued warrants to purchase total, shares | shares																																	583,334
Exercise price of warrants or rights | $ / shares																																	$ 20
Warrant maturity date																																	Dec. 14, 2025
Estimated value warrants																																	$ 7,680,156
Discount on convertable note and additional paid in capital																																	5,257,466
Debt instrument, unamortized discount																																	1,666,666
Loan fees																																	1,140,000
Debt amortized discount																																	8,064,132		4,241,429
Debt face amount																																			2,833,888
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]																															Convertible notes payable
Derivative liabilities																															$ 1,390,380
Accrued interest																																			$ 32,559
Debt converted into common stock | shares																																			8,527,835
Debt instrumment converted amount																																			$ 1,000,000
Extinguishment of derivative liability due to conversion																																			1,390,380
Amortization payment																																			3,001,442
Debt interest amount																																			167,554
Debt instrument aggregate principal amount
Two Convertible Notes [Member] | Terragenx Inc [Member]
Debt face amount																																		$ 1,875,000
Interest Rate, Stated Percentage																																		1%
Maturity date																																		May 17, 2022
Convertible Debt One [Member]
Debt face amount																																	8,333,333
Debt face amount																															1,000,000
Convertible Debt One [Member] | Terragenx Inc [Member]
Debt face amount																																		$ 937,500
Convertible Debt Two [Member]
Debt face amount																																	$ 8,333,333
Debt face amount																															$ 1,000,000
Convertible Debt Two [Member] | Terragenx Inc [Member]
Debt face amount																																		$ 937,500
Convertible Notes [Member] | Mast Hill Securities Purchase Agreement [Member]
Debt instrument, unamortized discount																																			269,123
Debt amortized discount																									$ 335,031										$ 65,908

Debentures, related parties (De

Debentures, related parties (Details Narrative)						12 Months Ended
	Nov. 02, 2021	Jul. 21, 2020 USD ($)	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 02, 2017	Sep. 30, 2013 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Sep. 30, 2013 CAD ($)
Short-Term Debt [Line Items]
Debentures, outstanding						$ 916,824	$ 946,250
Repayment of related party debt		$ 267,768				$ 7,206	$ 16,600
Five Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding					$ 6,225,163			$ 6,402,512
Debt interest rate					8%			8%
Debt due date	Dec. 01, 2023			Sep. 30, 2019	Sep. 30, 2016
Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding			$ 3,894,809
Percentage of debt converted			75%
Accrued interest			$ 414,965
Debt converted, shares issued | shares			1,047,588
Debt conversion price | $ / shares			$ 4.11
Debt conversion description			the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Schedule of Lease Related Asset

Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Leases
Operating lease assets	$ 1,983,898	$ 2,673,934
Total lease assets	1,983,898	2,673,934
Current liabilities- Operating lease liability	415,392	582,088
Noncurrent liabilities - Operating lease liability	1,693,577	2,185,329
Total lease liability	$ 2,108,969	$ 2,767,417

Schedule of Lease Obligations (

Schedule of Lease Obligations (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Leases
2024	$ 579,780
2025	510,085
2026	509,330
2027	472,291
2028	254,187
Thereafter	300,769
Total payments	2,626,442
Amount representing interest	(517,473)
Lease obligation, net	2,108,969	$ 2,767,417
Less lease obligation, current portion	(415,392)	(582,088)
Lease obligation, long-term portion	$ 1,693,577	$ 2,185,329

Schedule of Finance Leases (Det

Schedule of Finance Leases (Details)	Aug. 31, 2023 USD ($)
Leases
Cost	$ 209,457
Accumulated amortization	(209,457)
Net book value
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Leases
2024	$ 11,810
Total payments	11,810
Amount representing interest	(66)
Lease obligation, net	11,744
Less lease obligation, current portion	(11,744)	$ (8,890)
Lease obligation, long-term portion		$ 12,076

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Leases
Lease expense	$ 797,515	$ 852,580
Cash paid under operating leases	$ 772,655	$ 806,394
Weighted average remaning lease term	2 years 8 months 23 days
Weighted average discount rate	8%
Lease payments implicit borrowing rate	5%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Equity [Abstract]
Options outstanding, beginning balance	216,423	184,960
Weighted average exercise price, outstanding, beginning balance	$ 21.50	$ 22.90
Weighted average remaining contractual life, outstanding	3 years 11 months 23 days	2 years 6 months 10 days	3 years 1 month 20 days
Aggregate intrinsic value, outstanding, beginning balance	$ 140,577	$ 218,240
Options outstanding, granted	200,000	36,946
Weighted average exercise price, granted	$ 1.32	$ 14.60
Weighted average remaining contractual life, outstanding, granted	5 years 9 months	3 years 9 months 18 days
Options outstanding, expired	(45,000)
Options outstanding, forfeited		(5,483)
Options outstanding, exercised
Options outstanding, ending balance	371,423	216,423	184,960
Weighted average exercise price, outstanding, ending balance	$ 11.44	$ 21.50	$ 22.90
Aggregate intrinsic value, outstanding, ending balance	$ 16,000	$ 140,577	$ 218,240
Options outstanding, exercisable	371,423
Weighted average exercise price, exercisable	$ 11.44
Weighted average remaining contractual life, Exercisable	3 years 11 months 23 days
Aggregate intrinsic value, Exercisable	$ 16,000

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details) - $ / shares	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	371,423	216,423	184,960
Number of options, exercisable	371,423
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	22,715
Exercise price, outstanding	$ 13.30
Number of options, exercisable	22,715
Exercise price, exercisable	$ 13.30
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	54,200
Exercise price, outstanding	$ 16
Number of options, exercisable	54,200
Exercise price, exercisable	$ 16
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	4,800
Exercise price, outstanding	$ 18.70
Number of options, exercisable	4,800
Exercise price, exercisable	$ 18.70
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	77,500
Exercise price, outstanding	$ 30
Number of options, exercisable	77,500
Exercise price, exercisable	$ 30
Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	7,260
Exercise price, outstanding	$ 38
Number of options, exercisable	7,260
Exercise price, exercisable	$ 38
Exercise Price Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	1,000
Exercise price, outstanding	$ 50
Number of options, exercisable	1,000
Exercise price, exercisable	$ 50
Exercise Price Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	3,948
Exercise price, outstanding	$ 19
Number of options, exercisable	3,948
Exercise price, exercisable	$ 19
Exercise Price Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	200,000
Exercise price, outstanding	$ 1.32
Number of options, exercisable	200,000
Exercise price, exercisable	$ 1.32

Schedule of Fair Value of Optio

Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Risk-free interest rate	3.74%
Expected life of the options	6 years	2 years 6 months
Expected volatility	254%
Expected dividend yield	0%	0%
Minimum [Member]
Risk-free interest rate		0.93%
Expected volatility		267%
Maximum [Member]
Risk-free interest rate		3.01%
Expected volatility		281%

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Equity [Abstract]
Warrants outstanding, beginning balance	844,526	238,805
Weighted average exercise price, outstanding, beginning balance	$ 24.18	$ 33.50
Weighted average remaining contractual life, outstanding, beginning balance	3 years 6 months	5 years 1 month 13 days
Aggregate intrinsic value, outstanding, beginning balance
Warrants outstanding, granted	1,077,661	605,721
Weighted average exercise price, granted	$ 1.39	$ 20.50
Weighted average remaining contractual life, granted	3 years 6 months 3 days	3 years 3 months
Warrants outstanding, forfeited
Warrants outstanding, exercised	1,115,933
Warrants outstanding, exercised	(1,115,933)
Warrants outstanding, ending balance	806,254	844,526
Weighted average exercise price, outstanding, ending balance	$ 12.05	$ 24.18
Weighted average remaining contractual life, outstanding, ending balance	3 years 8 months 15 days
Aggregate intrinsic value, outstanding, ending balance	$ 106,960
Warrants outstanding, exercisable	806,254
Weighted average exercise price, exercisable	$ 12.05
Weighted average remaining contractual life, exercisable	3 years 8 months 15 days
Aggregate intrinsic value, exercisable	$ 106,960

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	806,254	844,526	238,805
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	261,193
Exercise Price, Outstanding and Exercisable	$ 33.50
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	267,400
Exercise Price, Outstanding and Exercisable	$ 1
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	277,661
Exercise Price, Outstanding and Exercisable	$ 2.50
Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	806,254

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Nov. 07, 2023

Nov. 06, 2023

Aug. 24, 2023

Aug. 21, 2023

Aug. 18, 2023

Aug. 17, 2023

Aug. 01, 2023

Jul. 03, 2023

Jun. 28, 2023

Jun. 20, 2023

Jun. 01, 2023

May 11, 2023

May 10, 2023

Mar. 17, 2023

Mar. 08, 2023

Mar. 06, 2023

Jan. 12, 2023

Jan. 05, 2023

Dec. 29, 2022

Jul. 20, 2022

Jul. 12, 2022

Jul. 05, 2022

Jun. 29, 2022

May 11, 2022

May 02, 2022

Apr. 07, 2022

Mar. 18, 2022

Feb. 24, 2022

Jan. 24, 2022

Dec. 20, 2021

Sep. 16, 2021

Feb. 09, 2021

Oct. 03, 2023

Aug. 31, 2023

Aug. 31, 2022

Dec. 14, 2021

Nov. 17, 2021

Jan. 16, 2018

Sep. 08, 2015

Accumulated Other Comprehensive Income (Loss) [Line Items]

Convertible preferred stock, shares authorized

1,000,000

1,000,000

Convertible preferred stock, par value

$ 0.001

$ 0.001

Convertible preferred stock, shares issued

0

0

Convertible preferred stock, shares outstanding

0

0

Common stock, shares authorized

499,000,000

499,000,000

Common stock, par value

$ 0.001

$ 0.001

Common stock, shares issued

15,759,325

3,118,063

Common stock, shares outstanding

15,759,325

3,118,063

Number of shares issued

400,000

Warrants to purchase common stock

22,388

Proceeds from the sale of common stock, net of offering costs

$ 1,795,000

Estimated shares granted for warrants

1,077,661

605,721

Expected Voltality

254%

Dividend yield

0%

0%

Risk free interet rate

3.74%

Expected life

6 years

2 years 6 months

Number of shares issued

522,777

Value of shares issued

$ 580,778

$ 9,968,140

$ 1,272,994

Proceeds of warrants

532,600

Number of shares issued

1,795,000

Debt instrument, face amount

$ 1,875,000

Common stock to be issued

$ 1,217,293

$ 9,474,807

Weighted average fair value options

$ 1.32

$ 13.72

Weighted-average exercise price

$ 1.32

$ 14.24

Stock option expense

$ 385,335

$ 426,690

2018 Incentiven Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

100,000

Number of shares available for future grant

86,490

2021 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

450,000

Number of shares available for future grant

75,463

Term of award description

the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022 and January 1, 2023. As of August 31, 2023, the 2021 Plan had 75,463 shares available for award

Terragenx [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issued for acquisition, shares

91,138

Convertible Debt [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

1,258

62,395

Debt instrument aggregate principal amount

$ 25,000

$ 1,244,444

Accrued interest

$ 143

3,405

Debt Holder One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

3,916,596

Value of shares issued

$ 3,825,307

Debt issuance date

Feb. 28, 2023

Debt Holder Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

4,503,644

Value of shares issued

$ 4,503,640

Debt issuance date

Feb. 28, 2023

Debt Holder Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

890,711

Value of shares issued

$ 757,103

Debt issuance date

Feb. 28, 2023

Warrant Holders One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

65,000

Exercise warrants term

3 years

Proceeds of warrants

$ 65,000

Warrant Holders Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

33,000

Exercise warrants term

5 years

Proceeds of warrants

$ 33,000

Warrant Holders Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

33,000

Exercise warrants term

3 years

Proceeds of warrants

$ 33,000

Debt Holder Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

53,812

53,783

107,595

Value of shares issued

$ 100,278

Warrant Holder Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

30,000

Warrants to purchase common stock

160,000

Exercise warrants term

5 years

3 years

Proceeds of warrants

$ 160,000

Number of shares issued

$ 30,000

Warrant Holder Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

100,000

Exercise warrants term

5 years

Proceeds of warrants

$ 100,000

Warrant Holder Six [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

30,000

Exercise warrants term

5 years

Proceeds of warrants

$ 30,000

Warrant Holder Seven [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

30,000

Exercise warrants term

3 years

Proceeds of warrants

$ 30,000

Warrantholder One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

20,800

Exercise warrants term

3 years

Number of shares issued

$ 20,800

Warrantholder Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

20,800

Exercise warrants term

5 years

Number of shares issued

$ 20,800

Warrantholder Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

10,000

Exercise warrants term

3 years

Number of shares issued

$ 10,000

Jefferson [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

236,511

Liquidated damages

$ 201,034

Liquidated damages charge

186,719

Liquidated damages interest

$ 14,315

Share Exchange Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

3,623

Shares issuance date

Oct. 26, 2022

Hudson Bay [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

291,667

Shares issuance date

Nov. 15, 2022

CVI [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

115,935

175,732

Shares issuance date

Nov. 15, 2022

Share Exchange Agreement Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

320,204

Shares issuance date

Jan. 25, 2023

Share Exchange Agreement Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

95,500

Shares issuance date

Feb. 24, 2023

Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

100,000

74,167

95,500

Shares issuance date

Mar. 22, 2023

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

75,000

75,000

5,000

Proceeds from issuance of restricted shares

$ 107,000

$ 65,500

Number of restricted shares

5,000

5,000

Shares issued during period for intellectual property

$ 64,500

$ 60,000

Separation and Release Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

33,500

Consulting and Services Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

5,000

3,500

Proceeds from issuance of restricted shares

$ 64,750

Escrow Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

200,000

Shares issuance date

Nov. 23, 2021

Shares held in escrow, value

$ 0

Contractor Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

5,000

Proceeds from issuance of restricted shares

$ 138,000

Number of restricted shares

2,500

Shares issued during period for intellectual property

$ 30,000

Contractor Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

2,500

Proceeds from issuance of restricted shares

$ 69,000

Number of restricted shares

6,500

Shares issued during period for intellectual property

$ 78,000

Membership Interest Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

5,000

80,000

Proceeds from issuance of restricted shares

$ 1,704,000

Share Exchange Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share issued price per share

$ 33.50

Number of restricted shares

15,896

30,000

22,500

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

267%

Risk free interet rate

0.93%

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

281%

Risk free interet rate

3.01%

Weighted average fair value options

$ 18.01

Weighted-average exercise price

$ 19

Maximum [Member] | 2015 Incentive Compensation Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

50,000

Maximum [Member] | Escrow Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt instrument, face amount

$ 1,875,000

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

400,000

Share issued price per share

$ 5

Unit offering description

The Company sold an aggregate of 400,000 units for aggregate gross proceeds of $2,000,000, consisting of 400,000 common stock, 400,000 warrants with a three-year term to purchase 400,000 shares of common stock at an exercise price of $5 per share, and 400,000 warrants with a five-year term to purchase 400,000 shares of common stock at an exercise price of $5 per share.

Cash fee

$ 140,000

Percentage of issuance of offering

7%

Proceeds from the sale of common stock, net of offering costs

$ 1,795,000

Number of shares issued

10,177,834

63,653

Value of shares issued

$ 10,178

$ 64

Number of shares issued

$ 400

Shares issued for acquisition, shares

80,000

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share issued price per share

$ 2.956

Proceeds from issuance of common stock

$ 2,000,000

Estimated shares granted for warrants

800,000

Fair value of warrant granted

$ 1,137,959

Dividend yield

0%

Debt instrument, face amount

$ 5,257,466

Warrant [Member] | Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

149.06%

Expected life

3 years

Warrant [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Risk free interet rate

2.55%

Warrant [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Expected Voltality

206.90%

Expected life

5 years

Warrant [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Risk free interet rate

2.89%

Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

400,000

Exercise warrants term

3 years

Warrants exercise price

$ 5

Common Stock One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

400,000

Warrant Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

400,000

Exercise warrants term

5 years

Warrants exercise price

$ 5

Common Stock Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

400,000

Subsequent Event [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Reverse stock split

1-for-10 reverse stock split

1-for-10 reverse stock split (the “Reverse Stock Split”) effective immediately after the close of trading on the Nasdaq Capital Market (“Nasdaq”) on November 6, 2023, and the Company’s common stock began trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023. As a result of the Reverse Stock Split, every 10 pre-split shares of common stock outstanding became one share of common stock, with fractional shares rounded up to the next higher whole share. The Reverse Stock Split did not affect the number of authorized shares of common stock, the par value of the common stock, or modify any rights or preferences of shares of the Company’s common stock

Subsequent Event [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of shares issued

240,400

Schedule of Effective and Statu

Schedule of Effective and Statutory Income Tax Rates (Details) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022
Pretax income (loss)	$ (13,214,552)	$ (32,849,215)
Expected income tax expense (benefit)	(3,550,349)	(8,828,761)
Stock based compensation	233,800	474,239
Change in valuation allowance	3,316,549	8,354,522
Total
Total percentage	0%	0%
CANADA
Combined statutory tax rate	26.50%	26.50%
Pretax income (loss)	$ (3,515,747)	$ (8,105,151)
Expected income tax expense (benefit)	$ (931,672)	$ (2,147,864)
Expected income tax expense (benefit), percentage	(26.50%)	(26.50%)
Stock based compensation
Stock based compensation, percentage	0%	0%
Change in valuation allowance	$ 931,672	$ 2,147,864
Change in valuation allowance, percentage	26.50%	26.50%
Total
Total percentage	0%	0%
UNITED STATES
Combined statutory tax rate	27%	27%
Pretax income (loss)	$ (9,698,805)	$ (24,744,064)
Expected income tax expense (benefit)	$ (2,618,677)	$ (6,680,897)
Expected income tax expense (benefit), percentage	(27.00%)	(27.00%)
Stock based compensation	$ 233,800	$ 474,239
Stock based compensation, percentage	9%	17.40%
Change in valuation allowance	$ 2,384,877	$ 6,206,658
Change in valuation allowance, percentage	18%	9.60%
Total
Total percentage	0%	0%

Schedule of the Deferred Tax As

Schedule of the Deferred Tax Assets (Details) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 15,839,947	$ 12,523,398
Total deferred tax asset	15,839,947	12,523,398
Less: valuation allowance	(15,839,947)	(12,523,398)
Total deferred tax asset
Intangible assets	(1,400,499)	(1,445,448)
Total deferred tax liability	(1,400,499)	(1,445,448)
Net deferred tax liability	$ (1,400,499)	$ (1,445,448)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Aug. 31, 2023	Aug. 31, 2022
Deferred tax valuation allowances	$ 15,839,947	$ 12,523,398
Operating loss carry forward	15,839,947	$ 12,523,398
UNITED STATES
Operating loss carry forward	10,124,095
CANADA
Operating loss carry forward	$ 10,055,712

Summary of Purchase Price Alloc

Summary of Purchase Price Allocation at Fair Value (Details) - USD ($)		12 Months Ended
	Mar. 17, 2022	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Business Acquisition [Line Items]
Cash and cash equivalents		$ 29,291
Inventory		42,273
Prepaid expenses and other current assets		398
Property and equipment		66,759
Intangible assets		1,179,361
Accounts payable and accrued expenses		(189,080)
CEBA loan		(47,766)
Minority interest		(97,311)
Purchase price		983,925
Goodwill		7,582,483	$ 7,825,844	$ 9,488,848
Canada Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		7,629
Property and equipment		8,813
Intangible assets		31,101
Minority interest		(25,401)
Purchase price		25,500
Accounts receivable		2,754
Goodwill		602
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		18,383
Prepaid expenses and other current assets		11,292
Property and equipment		9,475
Purchase price		235,125
Accounts receivable		44,289
Intangible asset		151,686
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		2,186
Purchase price	$ 1,704,000	1,704,000
Intangible asset		$ 1,701,814

Summary of Purchase Price (Deta

Summary of Purchase Price (Details) - USD ($)		12 Months Ended
	Mar. 17, 2022	Aug. 31, 2023
Business Acquisition [Line Items]
Cash
Common stock		983,925
Purchase price, total		983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock		25,500
Purchase price, total		25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock		235,125
Purchase price, total		235,125
Clinical Consultants International LLC [Member]
Business Acquisition [Line Items]
Cash
Common stock		1,704,000
Purchase price, total	$ 1,704,000	$ 1,704,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative)

12 Months Ended

Jul. 20, 2022 shares

Jun. 29, 2022 shares

May 11, 2022 shares

Mar. 17, 2022 USD ($) shares

Mar. 02, 2022 USD ($) $ / shares shares

Nov. 17, 2021 USD ($) $ / shares shares

Nov. 17, 2021 CAD ($) shares

Oct. 08, 2021 CAD ($) shares

Aug. 31, 2023 USD ($) shares

Aug. 31, 2022 USD ($)

Mar. 17, 2021 USD ($)

Mar. 09, 2021 USD ($)

Business Acquisition [Line Items]

Units issued for cash, net of offering costs, shares | shares

400,000

Stock Issued During Period, Value, New Issues

$ 1,795,000

Share price | $ / shares

$ 33.50

Business combination consideration transferred

983,925

Canada Corp [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

1,700

Business combination consideration transferred

25,500

Purchase price

$ 68,000

Purchase price per share | $ / shares

$ 40

Poling Taddeo Hovius Physiotherapy Professional Corp [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

15,675

Business combination consideration transferred

235,125

Purchase price

$ 627,000

Purchase price per share | $ / shares

$ 40

Clinical Consultants International LLC [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

80,000

Business combination consideration transferred

$ 1,704,000

1,704,000

Canada Corp [Member]

Business Acquisition [Line Items]

Ownership percentage

50.10%

Clinical Consultants International LLC [Member]

Business Acquisition [Line Items]

Ownership percentage

100%

Terragenx Inc [Member]

Business Acquisition [Line Items]

Ownership Percentage

91%

91%

Joint Venture Agreement [Member]

Business Acquisition [Line Items]

Proceeds from joint venture

$ 1,500,000

Units issued for cash, net of offering costs, shares | shares

185,000

Mullins Asset Purchase Agreement [Member]

Business Acquisition [Line Items]

Purchase of assets

$ 1,990,250

$ 2,500,000

Shares issued price per share | $ / shares

$ 33.50

Royalty paid description

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property.

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales reported through the Company or any of its wholly owned subsidiaries for a period equal to the commercial validity of the intellectual property.

Mullins Asset Purchase Agreement [Member] | Mr.Mullins [Member]

Business Acquisition [Line Items]

Stock Issued During Period, Value, New Issues

$ 1,592,200

$ 2,000,000

Shares issued, restricted stock, value

$ 398,050

$ 500,000

Number of restricted shares of common stock, shares | shares

11,883

11,883

Share price | $ / shares

$ 15.90

Asset acquisition consideration transferred

$ 188,925

Mullins Asset Purchase Agreement [Member] | Terragenx [Member] | Mr.Mullins [Member]

Business Acquisition [Line Items]

Number of shares issued, value

CAD$2,000,000 (approximately $1,592,200) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally, is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares will be held in escrow pending registration

CAD$2,000,000 (approximately $1,592,200) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally, is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares will be held in escrow pending registration

Mullins Asset [Member] | Mr.Mullins [Member]

Business Acquisition [Line Items]

Asset acquisition consideration transferred

$ 755,701

Share Exchange Agreement [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

15,896

30,000

22,500

Shares issued price per share | $ / shares

$ 33.50

Business combination consideration transferred

$ 398,050

$ 500,000

Share Exchange Agreement [Member] | Terragenx Inc [Member]

Business Acquisition [Line Items]

Units issued for cash, net of offering costs, shares | shares

100

100

Ownership Percentage

91%

91%

Shares exchanged, shares | shares

11,883

11,883

Share Exchange Agreement [Member] | Novo Healthnet Limited [Member]

Business Acquisition [Line Items]

Units issued for cash, net of offering costs, shares | shares

910

910

Share Exchange, Description

At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 shares of Terra common stock, representing 91% of Terra’s outstanding shares, and (ii) a total of 100 NHL Exchangeable Shares were issued to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of 11,883 restricted shares of the Company’s common stock. As a result of the Exchange, NHL has 91% ownership of Terra and full control of the Terra business.

At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 shares of Terra common stock, representing 91% of Terra’s outstanding shares, and (ii) a total of 100 NHL Exchangeable Shares were issued to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of 11,883 restricted shares of the Company’s common stock. As a result of the Exchange, NHL has 91% ownership of Terra and full control of the Terra business.

Share Exchange Agreement [Member] | Terragenx [Member]

Business Acquisition [Line Items]

Share price | $ / shares

$ 15.90

Business combination consideration transferred

$ 983,925

Share Exchange Agreement [Member] | Terragenx [Member] | Terry Mullins [Member]

Business Acquisition [Line Items]

Units issued for cash, net of offering costs, shares | shares

50,000

50,000

Cloud DX Amendment [Member] | Clinical Consultants International LLC [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business combination, recognized intangible assets

$ 317,314

$ 1,701,814

$ 1,701,814

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - 12 months ended Aug. 31, 2023	USD ($)	CAD ($)
Commitments and Contingencies Disclosure [Abstract]
Loss contingency	$ 369,500	$ 500,000

Schedule of Segment Reporting I

Schedule of Segment Reporting Information (Details) - USD ($)	12 Months Ended
	Aug. 31, 2023	Aug. 31, 2022	Aug. 31, 2021
Segment Reporting Information [Line Items]
Sales	$ 12,572,019	$ 11,737,937
Gross profit	4,952,715	4,799,238
Income (loss) from operations	(8,553,162)	(25,026,677)
Depreciation and amortization	2,302,754	3,019,253
Capital expenditures	49,224	3,600
Interest expenses	360,571	1,594,275
Net loss	(13,269,444)	(33,045,178)
Total assets	35,563,047	40,872,840
Accounts receivable	1,467,028	1,017,405
Intangible assets	16,218,539	18,840,619
Goodwill	7,582,483	7,825,844	$ 9,488,848
Healthcare Services [Member]
Segment Reporting Information [Line Items]
Sales	8,226,674	8,397,857
Gross profit	2,998,315	3,448,233
Income (loss) from operations	(413,670)	(1,506,135)
Depreciation and amortization	132,539	141,529
Capital expenditures
Interest expenses	92,327	76,255
Net loss	(496,970)	(1,408,891)
Total assets	5,158,851	5,917,403
Accounts receivable	697,440	585,492
Intangible assets	120,163	159,453
Goodwill	520,821	537,537
Product Sales [Member]
Segment Reporting Information [Line Items]
Sales	4,335,645	3,336,899
Gross profit	1,944,701	1,347,825
Income (loss) from operations	(2,958,225)	(4,940,559)
Depreciation and amortization	1,052,406	1,337,324
Capital expenditures	49,224	3,600
Interest expenses	55,441	962,480
Net loss	(3,193,859)	(7,305,571)
Total assets	17,993,652	19,595,269
Accounts receivable	765,388	419,417
Intangible assets	3,818,313	5,283,333
Goodwill	7,061,662	7,288,307
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Sales	9,700	3,181
Gross profit	9,699	3,180
Income (loss) from operations	(5,181,267)	(18,579,983)
Depreciation and amortization	1,117,809	1,540,400
Capital expenditures
Interest expenses	212,803	555,540
Net loss	(9,578,615)	(24,330,716)
Total assets	12,410,544	15,360,168
Accounts receivable	4,200	12,496
Intangible assets	12,280,063	13,397,832
Goodwill

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)																																			1 Months Ended	12 Months Ended
	Aug. 18, 2024 USD ($)	Aug. 12, 2024 USD ($)	Jul. 18, 2024 USD ($)	Jul. 12, 2024 USD ($)	Jun. 18, 2024 USD ($)	Jun. 12, 2024 USD ($)	May 18, 2024 USD ($)	May 12, 2024 USD ($)	Apr. 20, 2024 USD ($)	Apr. 18, 2024 USD ($)	Apr. 12, 2024 USD ($)	Mar. 20, 2024 USD ($)	Mar. 18, 2024 USD ($)	Mar. 12, 2024 USD ($)	Feb. 20, 2024 USD ($)	Jan. 20, 2024 USD ($)	Dec. 23, 2023 USD ($)	Dec. 20, 2023 USD ($)	Nov. 23, 2023 USD ($)	Nov. 21, 2023 USD ($)	Nov. 07, 2023	Nov. 06, 2023	Oct. 23, 2023 USD ($) shares	Oct. 12, 2023 USD ($) shares	Sep. 23, 2023 USD ($)	Sep. 18, 2023 USD ($) $ / shares shares	Sep. 12, 2023 USD ($) $ / shares shares	Sep. 12, 2023 CAD ($) shares	Aug. 23, 2023 USD ($)	Jun. 20, 2023 USD ($) $ / shares	Jun. 20, 2023 USD ($) $ / shares shares	May 20, 2023 USD ($)	Feb. 23, 2023 USD ($) $ / shares shares	Jan. 23, 2023 USD ($)	Oct. 03, 2023 shares	Aug. 31, 2023 USD ($) shares	Sep. 27, 2023 USD ($)	Sep. 12, 2023 CAD ($)	Nov. 21, 2022 $ / shares	Nov. 17, 2021 USD ($) $ / shares
Subsequent Event [Line Items]
Debt face amount																																								$ 1,875,000
Original issue discount																																								$ 375,000
Units issued for cash, net of offering costs, shares | shares																																				400,000
Share price | $ / shares																																								$ 33.50
Common Stock [Member]
Subsequent Event [Line Items]
Units issued for cash, net of offering costs, shares | shares																																				400,000
Share price | $ / shares																																							$ 1
Maximum [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Share price | $ / shares																																							1
Minimum [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Share price | $ / shares																																							$ 1
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split																					1-for-10 reverse stock split	1-for-10 reverse stock split (the “Reverse Stock Split”) effective immediately after the close of trading on the Nasdaq Capital Market (“Nasdaq”) on November 6, 2023, and the Company’s common stock began trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023. As a result of the Reverse Stock Split, every 10 pre-split shares of common stock outstanding became one share of common stock, with fractional shares rounded up to the next higher whole share. The Reverse Stock Split did not affect the number of authorized shares of common stock, the par value of the common stock, or modify any rights or preferences of shares of the Company’s common stock
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Units issued for cash, net of offering costs, shares | shares																																			240,400
Mast Hill Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Debt instrument, interest rate, effective percentage																														12%	12%		12%
Maturity date																															Jun. 20, 2024		Feb. 23, 2024
Debt face amount																														$ 445,000	$ 445,000		$ 573,000
Original issue discount																														$ 44,500	$ 44,500
Debt conversion price | $ / shares																														$ 1.75	$ 1.75		$ 1.75
Accrued liabilities																													$ 57,300	$ 445,000		$ 77,661		$ 100,000
Percentage of stock price trigger																															85%		85%
Administrative fees expense																															$ 750		$ 750
Variable interest, percentage rate																														125%	125%		125%
Units issued for cash, net of offering costs, shares | shares																															74,167
Share price | $ / shares																														$ 1.535	$ 1.535
Number of restricted shares of common stock, shares | shares																																	95,500
Mast Hill Securities Purchase Agreement [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Debt face amount																														$ 74,793	$ 74,793		$ 82,963
Mast Hill Securities Purchase Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Variable interest, percentage rate																														16%	16%		16%
Mast Hill Securities Purchase Agreement [Member] | Forecast [Member]
Subsequent Event [Line Items]
Accrued liabilities		$ 595,000		$ 595,000		$ 595,000		$ 350,000	$ 77,661		$ 350,000	$ 77,661		$ 350,000	$ 44,500	$ 44,500	$ 100,000	$ 445,000	$ 100,000				$ 57,300		$ 57,300
Mast Hill Securities Purchase Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument, interest rate, effective percentage																											12%											12%
Maturity date																											Sep. 12, 2024	Sep. 12, 2024
Debt face amount																											$ 3,500,000
Original issue discount																											350,000
Repayments of debt																											$ 3,150,000
Debt conversion price | $ / shares																											$ 4.50
Percentage of stock price trigger																											0.915	0.915
Percentage of stock price trigger																											85%	85%
Administrative fees expense																											$ 750
Variable interest, percentage rate																											125%											125%
Restructuring charges																												$ 1,600,000
Financial instruments owned, mortgages																																						$ 1,800,000
Units issued for cash, net of offering costs, shares | shares																											1,772,045	1,772,045
Mast Hill Securities Purchase Agreement [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Variable interest, percentage rate																											16%											16%
FirstFire Securities Purchase Agreement [Member] | Forecast [Member]
Subsequent Event [Line Items]
Accrued liabilities	$ 47,222		$ 47,222		$ 47,222		$ 27,778			$ 27,778			$ 27,778
FirstFire Securities Purchase Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument, interest rate, effective percentage																										12%
Maturity date																										Sep. 18, 2024
Debt face amount																										$ 277,778
Original issue discount																										27,778
Repayments of debt																										$ 250,000
Debt conversion price | $ / shares																										$ 4.50
Percentage of stock price trigger																										0.915
Percentage of stock price trigger																										85%
Administrative fees expense																										$ 750
Variable interest, percentage rate																										125%
Units issued for cash, net of offering costs, shares | shares																											480,156	480,156
FirstFire Securities Purchase Agreement [Member] | Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Variable interest, percentage rate																										16%
Master Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Collateral amount																																					$ 1,000,000,000
Ophir Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Security deposit																				$ 25,000
Repayments of related party																				60,000,000
Repayments of related party excluding deposit																				$ 59,975,000
Employment Agreement [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of restricted shares of common stock, shares | shares																																			737,642
Consulting Agreements [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of restricted shares of common stock, shares | shares																																			375,000
MastHill Warrant Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of restricted shares of common stock, shares | shares																							138,703			53,567
Proceeds from warrant exercises																							$ 445,000			$ 573,000
First Fire Warrant Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of restricted shares of common stock, shares | shares																								53,532
Proceeds from warrant exercises																								$ 573,000